var title_f2_32_2560="Common iliac artery with adequate landing zones";
var content_f2_32_2560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F74680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F74680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Common iliac artery with adequate landing zones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 299px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A common iliac artery aneurysm with adequate proximal and distal landing zones is managed with a common iliac artery stent-graft.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_32_2560=[""].join("\n");
var outline_f2_32_2560=null;
var title_f2_32_2561="Sodium stibogluconate: International drug information";
var content_f2_32_2561=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium stibogluconate: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Pentostam (GB, IL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F3466685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiprotozoal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F3466686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cutaneous and visceral leishmaniasis; treatment of South American mucocutaneous leishmaniasis",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3466688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution, as sodium: Equivalent to 100 mg of pentavalent antimony/mL (30 mL, 100 mL)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10505 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_32_2561=[""].join("\n");
var outline_f2_32_2561=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302638\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466685\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466686\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821150\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466688\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10505\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10505|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_32_2562="Lanolin, cetyl alcohol, glycerin, and petrolatum: Drug information";
var content_f2_32_2562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lanolin, cetyl alcohol, glycerin, and petrolatum: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lubriderm&reg; Fragrance Free [OTC];",
"     </li>",
"     <li>",
"      Lubriderm&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F186709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F186703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dry skin: Topical: Apply to skin as necessary",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F186704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F186698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical [bottle]: 180 mL, 300 mL, 480 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical [tube]: 100 mL",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F186688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F186699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of dry skin",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F186707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1% to 10%: Local irritation",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10081 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-46FA143880-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_32_2562=[""].join("\n");
var outline_f2_32_2562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186702\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186709\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186703\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186704\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186698\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186688\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186699\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186707\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10081\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10081|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_32_2563="Patient information: Biceps tendinopathy (The Basics)";
var content_f2_32_2563=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16297\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/37/12895\">",
"         Pendulum stretch exercise",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/8/13455\">",
"          Walk-up-wall stretch",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/47/38642\">",
"         Patient information: Elbow tendinopathy (tennis and golf elbow) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/26/22946\">",
"         Patient information: Frozen shoulder (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/53/29522\">",
"         Patient information: Rotator cuff injury (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/36/25153\">",
"         Patient information: Biceps tendinitis or tendinopathy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/18/44321\">",
"         Patient information: Elbow tendinopathy (tennis and golf elbow) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/49/24341\">",
"         Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Biceps tendinopathy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/biceps-tendinopathy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H24219156\">",
"      <span class=\"h1\">",
"       What is biceps tendinopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Biceps tendinopathy is a condition that can cause pain in the front of the shoulder. Doctors use the term &ldquo;biceps tendinopathy&rdquo; when people have a problem with their biceps tendon. The biceps is the muscle in the front of the upper arm. Tendons are strong bands of tissue that connect muscles to bones.",
"     </p>",
"     <p>",
"      In most people with biceps tendinopathy, the tendons are not inflamed or swollen. If they do get inflamed or swollen, doctors call it &ldquo;tendinitis.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24219163\">",
"      <span class=\"h1\">",
"       What causes biceps tendinopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;This condition can happen as people get older, especially if they do a lot of work or activity with their arms overhead. Tendinitis can happen if people hurt their upper arm or shoulder, or do the same movements over and over.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24219170\">",
"      <span class=\"h1\">",
"       What are the symptoms of biceps tendinopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptoms are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Pain in the front of the shoulder &mdash; The pain is usually worse at night and with lifting, pulling, or reaching overhead.",
"       </li>",
"       <li>",
"        Trouble moving the upper arm and shoulder",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with tendinitis can also have swelling.",
"     </p>",
"     <p>",
"      Sometimes, an injured tendon tears. This can cause a sudden &ldquo;pop,&rdquo; pain, bruising, or swelling.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24219177\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You might. Your doctor or nurse will talk with you and do an exam. He or she might also do an imaging test, such as an ultrasound or MRI scan. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24219184\">",
"      <span class=\"h1\">",
"       How is biceps tendinopathy treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most of the time, this condition will get better on its own, but it can take weeks to months to heal completely. To help your symptoms get better, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rest your arm and shoulder &mdash; Avoid lifting or reaching overhead. Try to keep your arm down, close to, and in front of your body.",
"       </li>",
"       <li>",
"        Ice the painful area &mdash; Put a cold gel pack, bag of ice, or bag of frozen vegetables on the injured area every 1 to 2 hours, for 15 minutes each time. Put a thin towel between the ice (or other cold object) and your skin.",
"       </li>",
"       <li>",
"        Take medicine to reduce the swelling and pain &mdash; To treat pain, you can take",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sample brand name: Tylenol&reg;). Your doctor might also recommend that you take a &ldquo;nonsteroidal anti-inflammatory drug&rdquo; or &ldquo;NSAID.&rdquo; NSAIDs are a group of medicines that includes",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your symptoms don&rsquo;t improve with these treatments, your doctor or nurse might recommend that you have physical therapy (work with an exercise expert). He or she might also recommend that you do exercises at home. The following shoulder exercises can help stretch your shoulder and keep it from getting too stiff:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Pendulum stretch &mdash; Let your arm relax and hang down, while you sit or stand. Move your arm back and forth, then side to side, and then around in small circles (",
"        <a class=\"graphic graphic_figure graphicRef50148 \" href=\"UTD.htm?12/37/12895\">",
"         figure 1",
"        </a>",
"        ). Try to do this exercise for 5 minutes, 1 or 2 times a day. Your doctor might suggest that you hold a weight in your hand when doing the exercise to make it harder.",
"       </li>",
"       <li>",
"        Wall walk &mdash; Face a wall, and stand close enough so that you can touch the wall with your fingertips. Stretch out your arm, parallel to the floor, and put your fingertips on the wall. Then walk your fingers up the wall until you feel mild soreness or aching. Keep your shoulders level (do not shrug them). Try to do this exercise for 5 minutes, 2 or 3 times a day (",
"        <a class=\"graphic graphic_picture graphicRef78109 \" href=\"UTD.htm?13/8/13455\">",
"         picture 1",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      When you do these exercises, it&rsquo;s important to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Warm up your shoulder first by taking a hot shower or bath, or putting a heating pad on it.",
"       </li>",
"       <li>",
"        Start slowly and make the exercises harder over time.",
"       </li>",
"       <li>",
"        Know that some soreness is normal. If you have sharp or tearing pain, stop what you&rsquo;re doing and let your doctor or nurse know.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24219191\">",
"      <span class=\"h1\">",
"       What if my symptoms don&rsquo;t get better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your symptoms don&rsquo;t get better, talk with your doctor or nurse about other possible treatments, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Getting a shot of medicine into the painful area",
"       </li>",
"       <li>",
"        Surgery",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24219198\">",
"      <span class=\"h1\">",
"       When will I be able to do my usual activities again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can return to your usual activities when you are able to move your arm in all directions without pain. To avoid hurting yourself, restart your activities or sports slowly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24219205\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/53/29522?source=see_link\">",
"       Patient information: Rotator cuff injury (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/26/22946?source=see_link\">",
"       Patient information: Frozen shoulder (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/47/38642?source=see_link\">",
"       Patient information: Elbow tendinopathy (tennis and golf elbow) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/36/25153?source=see_link\">",
"       Patient information: Biceps tendinitis or tendinopathy (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/49/24341?source=see_link\">",
"       Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/18/44321?source=see_link\">",
"       Patient information: Elbow tendinopathy (tennis and golf elbow) (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?2/32/2563?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16297 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-218.28.111.102-5CC63B1F68-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_32_2563=[""].join("\n");
var outline_f2_32_2563=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24219156\">",
"      What is biceps tendinopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24219163\">",
"      What causes biceps tendinopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24219170\">",
"      What are the symptoms of biceps tendinopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24219177\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24219184\">",
"      How is biceps tendinopathy treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24219191\">",
"      What if my symptoms don&rsquo;t get better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24219198\">",
"      When will I be able to do my usual activities again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24219205\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16297\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/37/12895\">",
"      Pendulum stretch exercise",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/8/13455\">",
"       Walk-up-wall stretch",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/36/25153?source=related_link\">",
"      Patient information: Biceps tendinitis or tendinopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/18/44321?source=related_link\">",
"      Patient information: Elbow tendinopathy (tennis and golf elbow) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/47/38642?source=related_link\">",
"      Patient information: Elbow tendinopathy (tennis and golf elbow) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/26/22946?source=related_link\">",
"      Patient information: Frozen shoulder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/53/29522?source=related_link\">",
"      Patient information: Rotator cuff injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/49/24341?source=related_link\">",
"      Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_32_2564="Fosfomycin: Patient drug information";
var content_f2_32_2564=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fosfomycin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/36/6724?source=see_link\">",
"     see \"Fosfomycin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F174319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Monurol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F174320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Monurol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691486",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat a bladder infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fosfomycin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696834",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 6 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       cup of water and drink it right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11947 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_32_2564=[""].join("\n");
var outline_f2_32_2564=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174319\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174320\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015540\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015539\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015544\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015545\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015547\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015542\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015543\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015548\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015549\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/36/6724?source=related_link\">",
"      Fosfomycin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_32_2565="Sodium phenylacetate and sodium benzoate: Pediatric drug information";
var content_f2_32_2565=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium phenylacetate and sodium benzoate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?7/21/7509?source=see_link\">",
"    see \"Sodium phenylacetate and sodium benzoate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/33/33299?source=see_link\">",
"    see \"Sodium phenylacetate and sodium benzoate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ammonul&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ammonium Detoxicant",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hyperammonemia Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Urea Cycle Disorder (UCD) Treatment Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12675757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Administer as a loading dose over 90-120 minutes, followed by an equivalent dose as a maintenance infusion over 24 hours. Arginine HCl is administered concomitantly. Dosage based on weight and specific enzyme deficiency; therapy should continue until ammonia levels are in normal range. Do not repeat loading dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CPS and OTC deficiency: Ammonul&reg; 2.5 mL/kg and arginine 10% 2 mL/kg (provides sodium phenylacetate 250 mg/kg, sodium benzoate 250 mg/kg",
"     <b>",
"      and",
"     </b>",
"     arginine hydrochloride 200 mg/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ASS and ASL deficiency: Ammonul&reg; 2.5 mL/kg and arginine 10% 6 mL/kg (provides sodium phenylacetate 250 mg/kg, sodium benzoate 250 mg/kg",
"     <b>",
"      and",
"     </b>",
"     arginine hydrochloride 600 mg/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Pending a specific diagnosis, the bolus and maintenance dose of arginine should be 6 mL/kg. If ASS or ASL are excluded as diagnostic possibilities, reduce dose of arginine to 2 mL/kg/day.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/21/7509?source=see_link\">",
"      see \"Sodium phenylacetate and sodium benzoate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Administer as a loading dose over 90-120 minutes, followed by an equivalent dose as a maintenance infusion over 24 hours. Arginine HCl is administered concomitantly. Dosage based on weight and specific enzyme deficiency; therapy should continue until ammonia levels are in normal range. Do not repeat loading dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children &le;20 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CPS and OTC deficiency: Ammonul&reg; 2.5 mL/kg and arginine 10% 2 mL/kg (provides sodium phenylacetate 250 mg/kg, sodium benzoate 250 mg/kg",
"     <b>",
"      and",
"     </b>",
"     arginine hydrochloride 200 mg/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ASS and ASL deficiency: Ammonul&reg; 2.5 mL/kg and arginine 10% 6 mL/kg (provides sodium phenylacetate 250 mg/kg, sodium benzoate 250 mg/kg",
"     <b>",
"      and",
"     </b>",
"     arginine hydrochloride 600 mg/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Pending a specific diagnosis in infants, the bolus and maintenance dose of arginine should be 6 mL/kg. If ASS or ASL are excluded as diagnostic possibilities, reduce dose of arginine to 2 mL/kg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;20 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CPS and OTC deficiency: Ammonul&reg; 55 mL/m",
"     <sup>",
"      2",
"     </sup>",
"     and arginine 10% 2 mL/kg (provides sodium phenylacetate 5.5 g/m",
"     <sup>",
"      2",
"     </sup>",
"     , sodium benzoate 5.5 g/m",
"     <sup>",
"      2",
"     </sup>",
"     <b>",
"      and",
"     </b>",
"     arginine hydrochloride 200 mg/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ASS and ASL deficiency: Ammonul&reg; 55 mL/m",
"     <sup>",
"      2",
"     </sup>",
"     and arginine 10% 6 mL/kg (provides sodium phenylacetate 5.5 g/m",
"     <sup>",
"      2",
"     </sup>",
"     , sodium benzoate 5.5 g/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"     <b>",
"      and",
"     </b>",
"     arginine hydrochloride 600 mg/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Use with caution; monitor closely",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dialysis: Ammonia clearance is &sim;10 times greater with hemodialysis than by peritoneal dialysis or hemofiltration. Exchange transfusion is ineffective.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Use with caution",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution [concentrate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ammonul&reg;: Sodium phenylacetate 100 mg and sodium benzoate 100 mg per 1 mL (50 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Must be administered via central line; administration via peripheral line may cause burns. Dilute in D",
"     <sub>",
"      10",
"     </sub>",
"     W at &ge;25 mL/kg prior to administration. May mix with arginine HCl. In case of extravasation, discontinue infusion and resume at new injection site.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F221939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Compatible",
"     </b>",
"     with arginine 10%.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1062246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prior to dilution, store at room temperature of 25&deg;C (77&deg;F). Following dilution in D",
"     <sub>",
"      10",
"     </sub>",
"     W, solution for infusion may be stored at room temperature for up to 24 hours. Stable when mixed with arginine HCl 10% injection",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to treatment of acute hyperammonemia and encephalopathy in patients with urea cycle disorders involving partial or complete deficiencies of carbamyl-phosphate synthetase (CPS), ornithine transcarbamoylase (OTC), argininosuccinate lysase (ASL), or argininosuccinate synthetase (ASS); for use with hemodialysis in acute neonatal hyperammonemic coma, moderate-to-severe hyperammonemic encephalopathy and hyperammonemia which fails to respond to initial therapy",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F221938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Nonspecific adverse reactions include: Nervous system disorders; metabolism and nutrition disorders; respiratory, thoracic, and mediastinal disorders; general disorders and injection site reactions; gastrointestinal disorders; blood and lymphatic system disorders; cardiac disorders; skin and subcutaneous tissue disorders; vascular disorders; psychiatric disorders; injury, poisoning, and procedural complications; renal and urinary disorders",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     More blood and lymphatic system, and vascular disorders were reported for patients &le;30 days of age; more gastrointestinal disorders were reported for patients &gt;30 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, brain edema, coma, mental impairment, pyrexia, seizures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, hyperammonemia, hyperglycemia, hypocalcemia, hypokalemia, metabolic acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, disseminated intravascular coagulation (DIC)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory distress",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal distention, acute psychosis, acute respiratory distress syndrome, aggression, alkalosis, alopecia, anuria, areflexia, ataxia, atrial rupture, blindness, blood carbon dioxide changes, blood glucose changes, blood pH increased, bradycardia, brain death, brain hemorrhage, brain herniation, brain infarction, cardiac arrest/failure, cardiac output decreased, cardiogenic shock, cardiomyopathy, cardiopulmonary arrest/failure, cerebral atrophy, chest pain, cholestasis, clonus, coagulopathy, confusion, consciousness depressed, dehydration, dyspnea, edema, encephalopathy, fluid overload/retention, flushing, gastrointestinal hemorrhage, hallucinations, hemangioma, hemorrhage, hepatic artery stenosis, hepatic failure, hepatotoxicity, hypercapnia, hyperkalemia, hypernatremia, hypertension, hyperventilation, injection site reaction (blistering, extravasation, hemorrhage), intracranial pressure increased, jaundice, Kussmaul respiration, maculopapular rash, multiorgan failure, nerve paralysis, pancytopenia, pCO2 changes, pericardial effusion, phlebothrombosis, pneumonia aspiration, pneumothorax, pruritus, pulmonary edema, pulmonary hemorrhage, rash, renal failure, respiratory alkalosis/acidosis, respiratory arrest/failure, respiratory rate increased, sepsis, septic shock, subdural hematoma, tetany, thrombocytopenia, thrombosis, tremor, urinary retention, urticaria, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sodium phenylacetate, sodium benzoate, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to high sodium content use with caution in patients with congestive heart failure, renal or hepatic dysfunction, or sodium retention associated with edema; maintain caloric intake at 80 cal/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1062241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severity of hyperammonemia may require hemodialysis, as well as nutritional management and medical support; due to enhanced potassium excretion, monitor potassium level closely; potential tissue extravasant which may result in skin necrosis, administer only through central I.V. line. Repeat loading doses are not indicated due to prolonged plasma levels noted in pharmacokinetic studies.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Sodium Phenylacetate. Specifically, probenecid may inhibit the renal transport of the phenylacetylglutamine metabolite of sodium phenylacetate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Sodium Benzoate. Specifically, probenecid may inhibit the renal transport of the hippuric acid metabolite of sodium benzoate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F221914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In animal studies, phenylacetate was shown to cause neurological toxicity. Reproduction studies have not been conducted with this combination.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1062249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neurologic status, plasma ammonia, plasma glutamine, clinical response, serum electrolytes (potassium or bicarbonate supplementation may be required), acid-base balance, infusion site",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1062252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term target levels (may not be appropriate for every patient):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Plasma ammonia: &lt;40 &mu;mol/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Plasma glutamine: &lt;1000 &mu;mol/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Normal plasma levels of alanine, glycine, lysine, arginine (except in arginase deficiency); normal urinary orotate excretion; normal plasma protein concentration",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium phenylacetate and sodium benzoate provide alternate pathways for the removal of ammonia through the formation of their metabolites. One mole of sodium phenylacetate removes two moles of nitrogen; one mole of sodium benzoate removes one mole of nitrogen.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and renal; sodium phenylacetate conjugates with glutamine, forming the active metabolite, phenylacetylglutamine (PAG); sodium benzoate combines with glycine to form the active metabolite hippuric acid (HIP)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1062258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ucephan&reg; (sodium phenylacetate and sodium benzoate), was previously available as an oral liquid for chronic treatment of urea cycle disorders. Although no longer commercially available, this combination may be compounded for patients not responsive to or tolerant of other treatments.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Batshaw ML, MacArthur RB, and Tuchman M, &ldquo;Alternative Pathway Therapy for Urea Cycle Disorders: Twenty Years Later,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 138(1 Suppl):46-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/32/2565/abstract-text/11148549 /pubmed\" id=\"11148549 \" target=\"_blank\">",
"        11148549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berry GT and Steiner RD, &ldquo;Long-Term Management of Patients With Urea Cycle Disorders,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 138(1 Suppl):56-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/32/2565/abstract-text/11148550/pubmed\" id=\"11148550\" target=\"_blank\">",
"        11148550",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brusilow SW, Danney M, Waber LJ, et al, &ldquo;Treatment of Episodic Hyperammonemia in Children With Inborn Errors of Urea Synthesis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1984, 310(25):1630-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/32/2565/abstract-text/6427608 /pubmed\" id=\"6427608 \" target=\"_blank\">",
"        6427608",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Consensus Statement From a Conference for the Management of Patients With Urea Cycle Disorders. Urea Cycle Disorders Conference Group,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 138(1 Suppl):1-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/32/2565/abstract-text/11148543/pubmed\" id=\"11148543\" target=\"_blank\">",
"        11148543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gutteridge C and Kuhn RJ, &ldquo;Compatibility of 10% Sodium Benzoate Plus 10% Sodium Phenylacetate With Various Flavored Vehicles,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1994, 51(19):2508, 2510.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/32/2565/abstract-text/7847413/pubmed\" id=\"7847413\" target=\"_blank\">",
"        7847413",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12951 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_32_2565=[""].join("\n");
var outline_f2_32_2565=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221922\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062250\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12675757\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062243\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221905\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221891\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062254\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221939\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062246\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062253\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221938\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062257\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062242\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062241\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300065\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223020\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221900\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221914\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062249\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062252\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062240\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062256\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062258\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12951\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12951|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/21/7509?source=related_link\">",
"      Sodium phenylacetate and sodium benzoate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/33/33299?source=related_link\">",
"      Sodium phenylacetate and sodium benzoate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_32_2566="Complications of cranial stereotactic radiosurgery";
var content_f2_32_2566=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of cranial stereotactic radiosurgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/32/2566/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/32/2566/contributors\">",
"     Brian Kavanagh, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/32/2566/contributors\">",
"     Kevin Lillehei, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/32/2566/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/32/2566/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/32/2566/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/32/2566/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/32/2566/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactic radiosurgery (SRS) involves the administration of a single or very limited number of high doses of ionizing radiation to a small, well-demarcated benign or malignant tumor or vascular malformation within the brain parenchyma, adjacent cerebral meninges, or base of skull region. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=see_link\">",
"     \"Stereotactic cranial radiosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The complications of SRS differ from those of conventional fractionated cranial irradiation because SRS is restricted to a small target volume and it utilizes a much higher dose in a single fraction. The toxicity of SRS is commonly divided into acute reactions occurring within 90 days of treatment and late reactions. The Radiation Therapy Oncology Group has published a grading scale for both acute and late central nervous system (CNS) toxicity following any form of radiotherapy (",
"    <a class=\"graphic graphic_table graphicRef64833 \" href=\"UTD.htm?23/32/24075\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73580 \" href=\"UTD.htm?9/0/9227\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The acute and late complications of SRS will be reviewed here, as well as specific complications associated with the most common applications of intracranial SRS. The complications of standard fractionation cranial irradiation and the results of treatment using SRS are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link\">",
"     \"Treatment of brain metastases in favorable prognosis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18584?source=see_link\">",
"     \"Vascular malformations of the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of the acute toxicity of stereotactic radiosurgery (SRS) was derived from a dose escalation study conducted by the Radiation Therapy Oncology Group (RTOG) in 156 patients with primary (36 percent) or recurrent metastatic brain tumors (64 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2566/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In this population, the maximum tolerated doses of single fraction SRS were established as 24 Gy, 18 Gy, and 15 Gy for tumors &le;20 mm, 21 to 30 mm, and 31 to 40 mm in maximum diameter, respectively. At these dose levels, the rates of acute grade 3 to 5 CNS toxicity ranged from 0 to 17 percent in the three groups, with the higher rates in patients with larger tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2566/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Severe",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subsequent experience based upon these tumor volume and dose recommendations suggest that severe acute reactions are rare. As an example, in one series that included 835 consecutive patients undergoing SRS, 18 had a neurologic event within seven days of treatment (eg, new focal deficit or seizure) and three died [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2566/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to dose, the location of the treated lesion may affect the incidence of post-SRS seizures. In a small series, seizures following radiotherapy were more common in patients whose lesions were located in the motor cortex rather than elsewhere in the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2566/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Less severe",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less severe neurologic symptoms are thought to be due to transient swelling that begins 12 to 48 hours after therapy. The spectrum of immediate side effects is illustrated by a study of 78 adults with a variety of intracranial lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2566/abstract/5\">",
"     5",
"    </a>",
"    ]. Within two weeks after SRS, approximately one-third developed mild nausea, dizziness or vertigo, seizures, or new headache. However, only two patients required hospitalization, including one with seizures and one with a worsening neurologic deficit. Higher RT doses were associated with a significantly increased incidence of immediate side effects.",
"   </p>",
"   <p>",
"    Acute toxicity generally is not predictive of the development of late toxicity. If a specific toxicity is anticipated, as with treatment near the area postrema (nausea center) in the brainstem, a short course of steroids is recommended around the time of radiosurgery. This generally eliminates the acute toxicity. While many patients will do well without prophylactic treatment, many physicians routinely prescribe a short course of steroids before",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    after radiosurgery unless there is a contraindication. The intent is to reduce the risk of headache or other symptoms that might occur as a result of transient post-radiosurgery edema in the treated volume. Matters of optimal dose and patient selection for steroids have not been addressed in formal clinical trials.",
"   </p>",
"   <p>",
"    In addition to its potential neurotoxicity, SRS involves immobilization of the patient's head in a rigid frame during treatment. The rigid head frame commonly used to immobilize patients is tightly fixed to the skull with pins that penetrate the skin. As a result, temporary discomfort and self-limited bruising at the pin placement sites can occur immediately following the procedure. Frameless positioning systems have been developed and could eliminate this problem [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2566/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LATE REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some authors distinguish \"subacute\" reactions that occur 3 to 10 months after SRS from more delayed late reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2566/abstract/9\">",
"     9",
"    </a>",
"    ]. However, this distinction is arbitrary, and the management of subacute and late reactions is driven by the nature of the complication, not the time frame following treatment. Late reactions often result in permanent sequelae but are sometimes reversible.",
"   </p>",
"   <p>",
"    Distinguishing delayed complications of SRS from symptoms of recurrent neoplasia can be difficult in patients with benign or malignant cranial tumors. In contrast, the use of SRS to treat arteriovenous malformations (AVM) has facilitated study of the effects of SRS on surrounding normal brain parenchyma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18584?source=see_link\">",
"     \"Vascular malformations of the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two reports illustrate the magnetic resonance (MRI) and clinical abnormalities that can occur in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 72 patients treated for AVMs, approximately one-third of patients manifested new regions of increased T2 signal hyperintensity on MRI in brain surrounding the AVM [",
"      <a class=\"abstract\" href=\"UTD.htm?2/32/2566/abstract/10\">",
"       10",
"      </a>",
"      ]. The changes were associated with headache or new neurologic deficits in approximately one-half of these cases. In most cases, the imaging changes and symptoms eventually resolved.",
"     </li>",
"     <li>",
"      A multi-institutional analysis of 1255 cases of AVM treated with SRS revealed radiation injury to the brain parenchyma, cranial nerve deficits, or seizures in 8 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/32/2566/abstract/11\">",
"       11",
"      </a>",
"      ]. The symptoms were usually described as minimal or mild. However, the toxicity was disabling in 21 (1.7 percent) and fatal in two patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Late toxicity in patients with benign or malignant tumors is also influenced by the type and location of the tumor. The potential complications are illustrated for the three most common applications of SRS: meningioma, vestibular schwannoma, and brain metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Meningioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;SRS is often administered as treatment for meningiomas arising in the region of the skull base, where surgical resection is limited by the presence of adjacent neurovascular structures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44616?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of benign (WHO grade I) meningioma\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two single institution series illustrate the potential complications in this population:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Mayo clinic experience, 206 meningiomas in 190 patients were treated with SRS, with 77 percent involving the skull base [",
"      <a class=\"abstract\" href=\"UTD.htm?2/32/2566/abstract/12\">",
"       12",
"      </a>",
"      ]. The median tumor margin dose was 16 Gy (range, 12 to 36 Gy). Overall, 13 percent experienced treatment-related complications. Specific side effects included cranial nerve deficits, symptomatic parenchymal changes, internal carotid artery stenosis, and symptomatic cyst formation in 8, 3, 1, and 1 percent of cases, respectively. Only 3 percent of patients had a reduction in functional status that was directly related to radiosurgery. Tumor volume, tumor margin dose, and a history of previous external beam radiotherapy were not correlated with the development of radiation-related complications.",
"     </li>",
"     <li>",
"      Similar results were seen in 99 consecutive patients treated at the University of Pittsburgh [",
"      <a class=\"abstract\" href=\"UTD.htm?2/32/2566/abstract/13\">",
"       13",
"      </a>",
"      ]. The mean tumor margin dose was 16 Gy. New or worsened neurologic deficits occurred in five patients within the first three years after SRS, including visual problems and transient hemiparesis. Complete resolution of symptoms was observed in two of these five patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vestibular schwannoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;SRS is a reasonable treatment option for patients with vestibular schwannomas (acoustic neuromas) less than 3 cm and for those with enlarging tumors who are not candidates for surgery. Hearing loss and facial or trigeminal nerve dysfunction are possible neurologic complications after SRS for acoustic neuromas. SRS also has been associated with hydrocephalus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2566/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following initial reports of variable rates of toxicity following SRS doses in the range of 15 Gy or higher, there has been a trend toward the routine use of more modest doses (12.5 to 13 Gy), with preservation of high tumor control rates and apparent reduction in the incidence of toxicity. Studies suggest that functional hearing is preserved in approximately 70 percent of patients, with higher rates among patients who have minimal impairment at baseline. Injury to cranial nerves V and VII are observed in 2 to 3 percent and 1 to 5 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2566/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40232?source=see_link&amp;anchor=H14#H14\">",
"     \"Vestibular schwannoma (acoustic neuroma)\", section on 'Stereotactic radiosurgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Brain metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;SRS is widely used in the treatment of patients with a single or limited number of brain metastases, either alone or in conjunction with WBRT. The actuarial incidence of radionecrosis following SRS in patients previously treated with irradiation for either primary or metastatic brain tumors was 5, 8, and 11 percent at 6, 12, and 24 months, respectively, in the original phase I study [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2566/abstract/2\">",
"     2",
"    </a>",
"    ]. Similar results were seen in a single institution cohort of 458 patients, with an overall incidence of radionecrosis of 5 percent with SRS doses of 18 to 20 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2566/abstract/18\">",
"     18",
"    </a>",
"    ]. In the EORTC study randomizing patients between surgery or SRS followed by either observation or whole brain radiotherapy, the incidence of radionecrosis after SRS alone was 1 percent (1 of 89) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2566/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the addition of an SRS boost to WBRT is associated with a higher incidence of both acute and delayed grade 3 or 4 toxicity (3 versus 0 and 6 versus 3 percent, compared with WBRT alone), despite providing an overall survival benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2566/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of brain metastases in favorable prognosis patients\", section on 'Stereotactic radiosurgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SECOND TUMORS AFTER SRS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other forms of ionizing irradiation, stereotactic radiosurgery (SRS) can be associated with the development of secondary malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2566/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Although the overall incidence appears very low, it is likely that the number of reported cases will increase as additional patients are treated and observed for extended periods. Thus, continued surveillance of treated patients should be considered, particularly those treated for benign conditions such as AVM's. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8874?source=see_link&amp;anchor=H9#H9\">",
"     \"Risk factors for brain tumors\", section on 'Ionizing radiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stereotactic radiosurgery (SRS) involves the administration of a single or very limited number of high doses of ionizing radiation to a small, well-demarcated benign or malignant tumor or vascular malformation within the brain parenchyma, adjacent meninges, or base of skull region. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=see_link\">",
"       \"Stereotactic cranial radiosurgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With appropriate limitation of radiation doses and treatment volume, severe acute reactions are rare. Less severe reactions (nausea, dizziness, seizures, new headache) may be seen within two weeks after treatment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Acute reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Late reactions are also rare, and generally are minimal or mild. In patients with an underlying tumor, these may be difficult to differentiate from tumor progression. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Late reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rare cases of secondary malignancies have been reported following stereotactic radiation surgery. However, prolonged follow-up on larger numbers of patients will be required to assess the frequency of this complication. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Second tumors after SRS'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/1\">",
"      Shaw E, Scott C, Souhami L, et al. Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: initial report of radiation therapy oncology group protocol (90-05). Int J Radiat Oncol Biol Phys 1996; 34:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/2\">",
"      Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 2000; 47:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/3\">",
"      Chin LS, Lazio BE, Biggins T, Amin P. Acute complications following gamma knife radiosurgery are rare. Surg Neurol 2000; 53:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/4\">",
"      Gelblum DY, Lee H, Bilsky M, et al. Radiographic findings and morbidity in patients treated with stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 1998; 42:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/5\">",
"      Werner-Wasik M, Rudoler S, Preston PE, et al. Immediate side effects of stereotactic radiotherapy and radiosurgery. Int J Radiat Oncol Biol Phys 1999; 43:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/6\">",
"      Murphy MJ, Chang SD, Gibbs IC, et al. Patterns of patient movement during frameless image-guided radiosurgery. Int J Radiat Oncol Biol Phys 2003; 55:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/7\">",
"      Takeuchi H, Yoshida M, Kubota T, et al. Frameless stereotactic radiosurgery with mobile CT, mask immobilization and micro-multileaf collimators. Minim Invasive Neurosurg 2003; 46:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/8\">",
"      Kamath R, Ryken TC, Meeks SL, et al. Initial clinical experience with frameless radiosurgery for patients with intracranial metastases. Int J Radiat Oncol Biol Phys 2005; 61:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/9\">",
"      Plowman PN. Stereotactic radiosurgery. VIII. The classification of postradiation reactions. Br J Neurosurg 1999; 13:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/10\">",
"      Flickinger JC, Lunsford LD, Kondziolka D, et al. Radiosurgery and brain tolerance: an analysis of neurodiagnostic imaging changes after gamma knife radiosurgery for arteriovenous malformations. Int J Radiat Oncol Biol Phys 1992; 23:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/11\">",
"      Flickinger JC, Kondziolka D, Lunsford LD, et al. A multi-institutional analysis of complication outcomes after arteriovenous malformation radiosurgery. Int J Radiat Oncol Biol Phys 1999; 44:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/12\">",
"      Stafford SL, Pollock BE, Foote RL, et al. Meningioma radiosurgery: tumor control, outcomes, and complications among 190 consecutive patients. Neurosurgery 2001; 49:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/13\">",
"      Kondziolka D, Levy EI, Niranjan A, et al. Long-term outcomes after meningioma radiosurgery: physician and patient perspectives. J Neurosurg 1999; 91:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/14\">",
"      Likhterov I, Allbright RM, Selesnick SH. LINAC radiosurgery and radiotherapy treatment of acoustic neuromas. Otolaryngol Clin North Am 2007; 40:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/15\">",
"      Foote KD, Friedman WA, Buatti JM, et al. Analysis of risk factors associated with radiosurgery for vestibular schwannoma. J Neurosurg 2001; 95:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/16\">",
"      Lunsford LD, Niranjan A, Flickinger JC, et al. Radiosurgery of vestibular schwannomas: summary of experience in 829 cases. J Neurosurg 2005; 102 Suppl:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/17\">",
"      Kano H, Kondziolka D, Khan A, et al. Predictors of hearing preservation after stereotactic radiosurgery for acoustic neuroma. J Neurosurg 2009; 111:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/18\">",
"      Petrovich Z, Yu C, Giannotta SL, et al. Survival and pattern of failure in brain metastasis treated with stereotactic gamma knife radiosurgery. J Neurosurg 2002; 97:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/19\">",
"      Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011; 29:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/20\">",
"      Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/21\">",
"      Balasubramaniam A, Shannon P, Hodaie M, et al. Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature. Neuro Oncol 2007; 9:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2566/abstract/22\">",
"      Sheehan J, Yen CP, Steiner L. Gamma knife surgery-induced meningioma. Report of two cases and review of the literature. J Neurosurg 2006; 105:325.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7056 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-4C9EBFD82E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_32_2566=[""].join("\n");
var outline_f2_32_2566=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Severe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Less severe",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LATE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Meningioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vestibular schwannoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SECOND TUMORS AFTER SRS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7056\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7056|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/32/24075\" title=\"table 1\">",
"      RTOG acute morbidity crit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/0/9227\" title=\"table 2\">",
"      RTOG late morbidity crit",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8874?source=related_link\">",
"      Risk factors for brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44616?source=related_link\">",
"      Treatment of benign (WHO grade I) meningioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=related_link\">",
"      Treatment of brain metastases in favorable prognosis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18584?source=related_link\">",
"      Vascular malformations of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40232?source=related_link\">",
"      Vestibular schwannoma (acoustic neuroma)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_32_2567="Intraoperative duplex renal system and ectopic ureter";
var content_f2_32_2567=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Duplex renal system with upper pole obstructed ectopic ureter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 435px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intraoperative image of duplex renal system with upper pole obstructed ectopic ureter (black arrows). The dilated upper pole ureter is ~6 times the normal size compared to normal lower pole ureter (white arrowheads). Note the course of the ectopic ureter is underneath the normal lower pole ureter. It is&nbsp;headed to an ectopic location past the bladder, which is mostly covered by the metal retractor blade.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_32_2567=[""].join("\n");
var outline_f2_32_2567=null;
var title_f2_32_2568="Pericardial involvement in systemic autoimmune diseases";
var content_f2_32_2568=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pericardial involvement in systemic autoimmune diseases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/32/2568/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/32/2568/contributors\">",
"     Massimo Imazio, MD, FESC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/32/2568/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/32/2568/contributors\">",
"     Jae K Oh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/32/2568/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/32/2568/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/32/2568/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1817334\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic autoimmune diseases, also known as systemic inflammatory diseases, are inflammatory syndromes involving at least two organ systems. Classical systemic inflammatory diseases include connective tissue diseases, vasculitis, and granulomatous diseases (",
"    <a class=\"graphic graphic_table graphicRef70616 \" href=\"UTD.htm?34/53/35675\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/1\">",
"     1",
"    </a>",
"    ]. Cardiac involvement is not uncommon in systemic inflammatory diseases, although major cardiac problems are not usually the presenting manifestation. The reported frequency of cardiac involvement is variable depending on the applied diagnostic methods and patient selection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/1\">",
"     1",
"    </a>",
"    ]. Technological improvements in imaging modalities and the increasing availability of diagnostic imaging have revealed a higher frequency of cardiac abnormalities in patients with systemic inflammatory diseases than in older autopsy studies.",
"   </p>",
"   <p>",
"    Systemic inflammatory diseases may affect the pericardium (pericarditis and pericardial effusion), myocardium (myocarditis, cardiomyopathy, rhythm and conduction disturbances, heart failure), coronary arteries (acute coronary syndromes, ischemic heart disease), endocardium (valvular disease, thrombi), and major vessels (aneurysm formation, arterial and venous thrombosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. On rare occasions, pericardial effusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pericarditis may be the first clues of a systemic inflammatory disease or a manifestation of a known systemic disease. In these cases, pericardial involvement generally reflects the activity of the systemic disease.",
"   </p>",
"   <p>",
"    This topic will focus on the pericardial complications of systemic autoimmune diseases. A detailed discussion of non-pericardial cardiac manifestations of systemic autoimmune diseases is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22456?source=see_link\">",
"     \"Non-coronary cardiac manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\", section on 'Cardiac disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=see_link\">",
"     \"Cardiac sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H814260\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION, DIAGNOSIS, AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common types of pericardial involvement with systemic inflammatory diseases are acute (or recurrent) pericarditis and asymptomatic pericardial effusions. Pericardial involvement in systemic inflammatory disease is thought to be immune-mediated, although concomitant infection may play a role in some cases. Systemic inflammatory diseases may be either \"etiologic\" or \"permissive\" of increased susceptibility to an unrelated primary cause (eg, viral) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While some patients may manifest with the typical signs and symptoms of pericarditis (fever, pleuritic chest pain) or a hemodynamically significant effusion (dyspnea, fatigue, hypotension), many are incidentally found to have pericardial involvement during other testing (electrocardiography, echocardiography, computed tomography of the chest, or magnetic resonance imaging of the heart). Symptoms of pericardial involvement in systemic inflammatory disease may be insidious or may present suddenly with rapid progression. Cardiac tamponade and constrictive pericarditis are possible, but rare, complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis and treatment of pericardial effusion\", section on 'Diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A definitive diagnosis of pericardial involvement in systemic inflammatory diseases requires the finding of specific histological lesions in the pericardium or of characteristic pericardial fluid features [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/2\">",
"     2",
"    </a>",
"    ]. However, in clinical practice, the diagnosis is often presumptive, especially when pericardial fluid or tissue is not available (as in mild pericardial involvement with small to moderate effusions that are responsive to medical therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link&amp;anchor=H2299910#H2299910\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\", section on 'Identifying the etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnosis and treatment of pericardial effusion\", section on 'Establish the cause of the effusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment approach to pericardial involvement in systemic inflammatory diseases is dependent on symptoms. When a patient with pericardial involvement is asymptomatic, treatment is essentially that of the underlying systemic disease. Patients with a hemodynamically significant pericardial effusion should have the fluid drained (eg, pericardiocentesis or pericardiotomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/3\">",
"     3",
"    </a>",
"    ]. Most patients with symptoms of acute pericarditis should be treated with nonsteroidal antiinflammatory drugs (NSAIDs) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef56484 \" href=\"UTD.htm?40/35/41532\">",
"     table 2",
"    </a>",
"    ). In select patients with refractory symptoms despite optimal medical therapy, case reports suggest that the interleukin receptor blocker",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    may be effective in reducing symptoms and signs of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11177?source=see_link&amp;anchor=H12#H12\">",
"     \"Recurrent pericarditis\", section on 'Other immune therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, a patient may develop constrictive pericarditis, which may well respond to NSAIDs or steroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis and treatment of pericardial effusion\", section on 'Pericardial fluid analysis and biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link&amp;anchor=H27#H27\">",
"     \"Cardiac tamponade\", section on 'Removal of pericardial fluid'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/44/713?source=see_link\">",
"     \"Treatment of acute pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H814268\">",
"    <span class=\"h1\">",
"     SPECIFIC SYSTEMIC INFLAMMATORY DISEASES WITH PERICARDIAL INVOLVEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1817357\">",
"    <span class=\"h2\">",
"     Connective tissue diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardial involvement, especially asymptomatic, is relatively common in many connective tissue diseases (",
"    <a class=\"graphic graphic_table graphicRef59544 \" href=\"UTD.htm?17/26/17836\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1817364\">",
"    <span class=\"h3\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardial involvement may precede the clinical signs of systemic lupus erythematosus (SLE). Pericardial involvement, typically a pericardial effusion, is the most common type of echocardiographic abnormality found in SLE, being reported in &gt;50 percent of patients, and is usually asymptomatic. Large",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemodynamically significant effusions resulting in cardiac tamponade are rare in SLE, as is the late development of constrictive pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. When pericardial fluid is available for analysis, specific findings may include antinuclear antibodies, phagocytic cells containing nuclei, low complement levels, and immune complexes similar to those seen in pleural effusions. However, in clinical practice, such findings in pericardial fluid add little to similar tests performed on a patient&rsquo;s serum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22456?source=see_link&amp;anchor=H8#H8\">",
"     \"Non-coronary cardiac manifestations of systemic lupus erythematosus in adults\", section on 'Pericardial disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pericarditis is the second most frequent type of pericardial involvement, either acute or recurrent. Pericarditis often occurs when SLE is active and may be associated with other types of serositis (ie, pleural effusion, ascites). The course is generally benign in the large majority of patients with pericardial disease. When symptomatic, however, patients with pericarditis usually respond to nonsteroidal antiinflammatory drugs (NSAIDs) (",
"    <a class=\"graphic graphic_table graphicRef56484 \" href=\"UTD.htm?40/35/41532\">",
"     table 2",
"    </a>",
"    ). When given along with NSAIDs,",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/colchicine-drug-information?source=see_link\">",
"     colchicine",
"    </a>",
"    &nbsp;may reduce the risk of recurrent pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Patients who do not tolerate or respond to NSAIDs and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    can be treated with a corticosteroid, usually",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/prednisone-drug-information?source=see_link\">",
"     prednisone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/44/713?source=see_link&amp;anchor=H12602665#H12602665\">",
"     \"Treatment of acute pericarditis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1817371\">",
"    <span class=\"h3\">",
"     Rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disorder that primarily involves joints, although&nbsp;extraarticular features (eg, anemia, fatigue, pleuropericarditis, neuropathy, renal disease) may occur. During the course of their disease, &lt;10 percent of patients with rheumatoid arthritis will develop pericarditis, although up to one-third have pericardial effusions which are usually asymptomatic. Pericarditis occurs most frequently in patients with active rheumatoid disease and other extra-articular manifestations. As such, most patients with symptomatic pericarditis have a positive serum test for rheumatoid factor. Management should be aimed at the control of the rheumatoid arthritis, though NSAIDs and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    can be given for symptomatic pericarditis (",
"    <a class=\"graphic graphic_table graphicRef56484 \" href=\"UTD.htm?40/35/41532\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/12\">",
"     12",
"    </a>",
"    ]. Occasionally, patients with RA develop constrictive pericarditis requiring pericardiectomy as definitive treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1817378\">",
"    <span class=\"h3\">",
"     Adult Still's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Still's disease (also called systemic onset juvenile inflammatory arthritis) is an inflammatory disorder characterized by daily fevers, arthritis, and an evanescent, salmon-colored rash typically found on the trunk. In the 70s, the term \"adult Still's disease\" (ASD) was used to describe a series of adult patients who did not fulfill criteria for classic rheumatoid arthritis (RA) but had features similar to the children with systemic onset juvenile RA. Pericarditis has been reported in up to one-third of patients, and myocarditis in about 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/3/11320?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult Still's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1817437\">",
"    <span class=\"h3\">",
"     Systemic sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic sclerosis is an autoimmune disorder in which the characteristic skin changes of scleroderma are present in association with internal organ involvement. When present, cardiac complications are most commonly secondary to systemic or pulmonary hypertension, but primary cardiac involvement also occurs. Symptomatic pericarditis occurs in 7 to 20 percent of patients with systemic sclerosis, but pathologic evidence of pericardial involvement is observed in 70 to 80 percent of patients at autopsy. Pericardial effusions may be small or large and can develop rapidly, also leading to cardiac tamponade [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Patients with symptomatic cardiac involvement due to systemic sclerosis (SS) have a poor prognosis, with two- and five-year mortality rates of approximately 60 and 75 percent, respectively. When pericardial effusion is present along with pulmonary hypertension, the prognosis is worse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\", section on 'Cardiac disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1817430\">",
"    <span class=\"h3\">",
"     Dermatomyositis and polymyositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both polymyositis and dermatomyositis are classified as idiopathic inflammatory myopathies. While both dermatomyositis and polymyositis share the clinical feature of muscle weakness, dermatomyositis is also associated with a variety of characteristic skin manifestations. Cardiac involvement in polymyositis and dermatomyositis usually is asymptomatic and rarely the principal clinical feature at the time of initial presentation. Pericardial involvement is less common than for other connective tissue diseases (&lt;10 percent) and may be manifested by acute pericarditis, pericardial effusion, and cardiac tamponade [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1817423\">",
"    <span class=\"h3\">",
"     Mixed connective tissue disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed connective tissue disease (MCTD) is a generalized connective tissue disorder characterized by the presence of high titer anti-U1 ribonucleoprotein antibodies in combination with clinical features commonly seen in systemic lupus erythematosus, scleroderma, and polymyositis. Pericarditis is a relatively common clinical manifestation in MCTD, being reported in 10 to 30 percent of patients. However, pericardial tamponade is rare. Involvement of the myocardium is also increasingly recognized in MCTD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43401?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations of mixed connective tissue disease\", section on 'Cardiac disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1817416\">",
"    <span class=\"h3\">",
"     Sj&ouml;gren's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sj&ouml;gren's syndrome is a chronic inflammatory disorder characterized by diminished lacrimal and salivary gland function, although extraglandular disease involvement can involve nearly any organ. Cardiovascular involvement occurs in less than one-third of cases and is usually asymptomatic. Pericarditis (both acute and recurrent) is the most common form of cardiac involvement in Sj&ouml;gren's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\", section on 'Heart'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1817393\">",
"    <span class=\"h2\">",
"     Other disease entities",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1817401\">",
"    <span class=\"h3\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that is characterized pathologically by the presence of noncaseating granulomas in involved organs. Clinical manifestations of cardiac sarcoidosis depend upon the location and extent of granulomatous inflammation. Cardiac involvement (which affects about 25 percent of patients) may precede, follow, or occur concurrently with involvement of the lungs or other organs. Clinicians should consider the possibility of sarcoid heart disease in the evaluation of an otherwise healthy young or middle-aged person with cardiac symptoms or of a patient with known sarcoidosis who develops arrhythmias, conduction disease, or heart failure. Mild to moderate asymptomatic pericardial effusions are commonly detected. However, symptomatic pericarditis is rare during the course of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=see_link\">",
"     \"Cardiac sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H771997\">",
"    <span class=\"h3\">",
"     Pericarditis in acute rheumatic fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute rheumatic fever can occur two to four weeks following group A streptococcus pharyngitis and may consist of arthritis, carditis, chorea, erythema marginatum, and subcutaneous nodules. Rheumatic fever in general and pericarditis associated with rheumatic fever have become relatively rare in developed countries due to the routine use of antibiotics for pharyngitis. Acute pericarditis is a sign of active rheumatic carditis, usually occurring at the initial episode in the first week following fever and arthritis. Occasionally pericarditis may be the first sign of acute rheumatic fever. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pericardial rub is generally intense, and pericardial effusion is common although cardiac tamponade is generally rare. On this basis, rheumatic fever-associated pericarditis without definite carditis should be suspected in the presence of fever and arthritis in a young patient with serologic testing that is positive for beta-hemolytic streptococci. Treatment of pericarditis associated with rheumatic fever is the same as other causes of acute pericarditis (",
"    <a class=\"graphic graphic_table graphicRef56484 \" href=\"UTD.htm?40/35/41532\">",
"     table 2",
"    </a>",
"    ), with NSAIDs and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    as first line treatment options. Corticosteroids may be prescribed in cases of NSAID failure or contraindication [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/44/713?source=see_link&amp;anchor=H12602665#H12602665\">",
"     \"Treatment of acute pericarditis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H340783\">",
"    <span class=\"h3\">",
"     Vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vasculitides are defined by the presence of inflammatory leukocytes in vessel walls with reactive damage to mural structures. Loss of vessel integrity may lead to bleeding. Luminal compromise leads to downstream tissue ischemia and necrosis. Vasculitis may occur as a primary process or may be secondary to another underlying disease. In general, affected vessels vary in size, type, and location in association with the specific vasculitic disorder. Classically, the vasculitic syndromes have been categorized by the predominant sizes of the involved blood vessels (",
"    <a class=\"graphic graphic_table graphicRef79462 \" href=\"UTD.htm?36/61/37852\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link&amp;anchor=H2#H2\">",
"     \"Classification of and approach to the vasculitides in adults\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of vasculitis should be considered in patients who present with systemic symptoms in combination with evidence of single",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    multiorgan dysfunction. Although neither sensitive nor specific, common complaints and signs of vasculitis include fatigue, weakness, fever, arthralgias, abdominal pain, hypertension, renal insufficiency (with an active urine sediment containing red and white cell and occasionally red cell casts), and neurologic dysfunction. Pericardial involvement is relatively rare in large vessel vasculitis (eg, Takayasu arteritis and giant cell arteritis), while it is more common in medium to small vessels vasculitis (",
"    <a class=\"graphic graphic_table graphicRef59544 \" href=\"UTD.htm?17/26/17836\">",
"     table 3",
"    </a>",
"    ), especially Kawasaki Disease, allergic granulomatosis and angiitis (Churg-Strauss Syndrome), and granulomatosis with polyangiitis (Wegener's) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/22-30\">",
"     22-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H340998\">",
"    <span class=\"h4\">",
"     Beh&ccedil;et's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beh&ccedil;et's disease is a relapsing inflammatory disease with recurrent aphthous stomatitis, genital ulcerations, and uveitis as the most typical manifestations. Among the systemic vasculitides, Beh&ccedil;et's disease is remarkable for its ability to involve blood vessels of all sizes (small, medium, and large) on both the arterial and venous sides of the circulation. Arterial disease is most commonly a small vessel vasculitis, but medium and large vessel disease may also develop. Perivascular and endovascular inflammation may lead to hemorrhage, stenosis, aneurysm formation, thrombus formation in both arteries and veins, and varices. On the contrary, atherosclerosis does not appear to occur at an accelerated rate in Beh&ccedil;et's disease, as has been observed in other autoimmune diseases such as systemic lupus erythematosus. Symptomatic cardiac disease, such as aortic regurgitation, is possible in Beh&ccedil;et's disease, although most manifestations are vascular. Pericarditis, either acute or recurrent, has been reported, but it is relatively rare [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\", section on 'Cardiac disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1817385\">",
"    <span class=\"h1\">",
"     AUTOINFLAMMATORY DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As emerging causes of pericarditis, especially recurrent pericarditis, autoinflammatory diseases are characterized by a primary dysfunction of the immune system, mostly caused by mutations of genes involved in the regulation or activation of the inflammatory response without any apparent involvement of antigen-specific T cells or significant production of autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/32\">",
"     32",
"    </a>",
"    ]. These disorders usually manifest in the pediatric population, with onset ranging from the first hours to the first decade of life. However, a limited number of patients experience disease onset during adulthood. The most common autoinflammatory syndromes are familial Mediterranean fever and tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/33-36\">",
"     33-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341116\">",
"    <span class=\"h2\">",
"     Familial Mediterranean Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial Mediterranean Fever (FMF) is a disorder characterized by sporadic, paroxysmal attacks of fever and serosal inflammation. FMF is an autosomal recessive disease largely restricted to several ethnic groups originating in the Mediterranean region (Sephardic Jews, Armenians, Turks, North Africans, Arabs, and less commonly Greeks and Italians). However, the disease may be not restricted to these groups. In the United States, for example, FMF may be encountered in Ashkenazi Jews. Pericarditis, sometime recurrent but usually self-limiting, has been reported in patients with FMF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial Mediterranean fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341124\">",
"    <span class=\"h2\">",
"     Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;TRAPS, while rare, is the most common autosomal dominant autoinflammatory disorder and is caused by mutations in the TNFRSF1A gene encoding the 55-kD receptor for tumour necrosis factor-(TNF)-alpha. Particular hallmarks of TRAPS include the protracted duration of febrile attacks; rash, eye, and periorbital involvement in more than 80 percent of patients; and the nearly uniform presence of focal myalgias.",
"   </p>",
"   <p>",
"    Recurrent pericarditis is a common feature of TRAPS, but it rarely occurs alone [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Familial clustering of pericarditis has been recently reported in 5 to 10 percent of TRAPS patients with recurrent pericarditis, thus suggesting in some cases a possible genetic predisposition [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/36\">",
"     36",
"    </a>",
"    ]. Familial clustering,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    failure, and need of immunosuppressive therapies may represent clues for investigating mutations related to autoinflammatory diseases in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2568/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28551?source=see_link\">",
"     \"Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1817492\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic autoimmune diseases, also known as systemic inflammatory diseases, are inflammatory syndromes involving at least two organ systems. Cardiac involvement (affecting the pericardium, myocardium, endocardium, and coronary arteries) is not uncommon in systemic inflammatory diseases, although major cardiac problems are not usually the presenting manifestation. (See",
"      <a class=\"local\" href=\"#H1817334\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pericardial involvement in seen in a variety of systemic inflammatory diseases, including systemic lupus erythematosus, rheumatoid arthritis, adult Still&rsquo;s disease, systemic sclerosis, dermatomyositis, polymyositis, mixed connective tissue disease, Sj&ouml;gren's syndrome, sarcoidosis, rheumatic fever, and the vasculitides. (See",
"      <a class=\"local\" href=\"#H814268\">",
"       'Specific systemic inflammatory diseases with pericardial involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common types of pericardial involvement with systemic inflammatory diseases are acute (or recurrent) pericarditis and asymptomatic pericardial effusions. While some patients may manifest with the typical signs and symptoms of pericarditis (fever, pleuritic chest pain) or a hemodynamically significant effusion (dyspnea, fatigue, hypotension), many are incidentally found to have pericardial involvement during other testing (electrocardiography, echocardiography, computed tomography of the chest). Rarely, constrictive pericarditis can develop due to marked inflammation of the pericardium, and it may respond to NSAIDs or steroid therapy. (See",
"      <a class=\"local\" href=\"#H814260\">",
"       'Clinical presentation, diagnosis, and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment approach to pericardial involvement in systemic inflammatory diseases is dependent on symptoms:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When a patient with pericardial involvement is asymptomatic, treatment is essentially that of the underlying systemic disease. (See",
"      <a class=\"local\" href=\"#H814260\">",
"       'Clinical presentation, diagnosis, and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a hemodynamically significant pericardial effusion should have the fluid drained (eg, pericardiocentesis or pericardiotomy). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link&amp;anchor=H27#H27\">",
"       \"Cardiac tamponade\", section on 'Removal of pericardial fluid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most patients with symptoms of acute pericarditis should be treated with nonsteroidal antiinflammatory drugs (NSAIDs) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef56484 \" href=\"UTD.htm?40/35/41532\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/44/713?source=see_link&amp;anchor=H12602665#H12602665\">",
"       \"Treatment of acute pericarditis\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two autoinflammatory diseases, Familial Mediterranean Fever and tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS), are emerging causes of pericarditis, especially recurrent pericarditis. (See",
"      <a class=\"local\" href=\"#H1817385\">",
"       'Autoinflammatory diseases'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/1\">",
"      Knockaert DC. Cardiac involvement in systemic inflammatory diseases. Eur Heart J 2007; 28:1797.",
"     </a>",
"    </li>",
"    <li>",
"     Spodick DH. Pericardial disease in the vasculitis-connective tissue disease group. In: The Pericardium. A comprehensive textbook, Marcel Dekker, New York 1997. p.314-33.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/3\">",
"      Imazio M, Spodick DH, Brucato A, et al. Controversial issues in the management of pericardial diseases. Circulation 2010; 121:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/4\">",
"      Scardapane A, Brucato A, Chiarelli F, Breda L. Efficacy of an Interleukin-1&beta; Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis. Pediatr Cardiol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/5\">",
"      Vassilopoulos D, Lazaros G, Tsioufis C, et al. Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra). Int J Cardiol 2012; 160:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/6\">",
"      Picco P, Brisca G, Traverso F, et al. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum 2009; 60:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/7\">",
"      Haley JH, Tajik AJ, Danielson GK, et al. Transient constrictive pericarditis: causes and natural history. J Am Coll Cardiol 2004; 43:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/8\">",
"      Langley RL, Treadwell EL. Cardiac tamponade and pericardial disorders in connective tissue diseases: case report and literature review. J Natl Med Assoc 1994; 86:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/9\">",
"      Doria A, Iaccarino L, Sarzi-Puttini P, et al. Cardiac involvement in systemic lupus erythematosus. Lupus 2005; 14:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/10\">",
"      Imazio M, Brucato A, Trinchero R, et al. Colchicine for pericarditis: hype or hope? Eur Heart J 2009; 30:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/11\">",
"      Tincani A, Rebaioli CB, Taglietti M, Shoenfeld Y. Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus. Rheumatology (Oxford) 2006; 45 Suppl 4:iv8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/12\">",
"      Voskuyl AE. The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology (Oxford) 2006; 45 Suppl 4:iv4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/13\">",
"      Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still's disease. Ann Rheum Dis 2006; 65:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/14\">",
"      Parvez N, Carpenter JL. Cardiac tamponade in Still disease: a review of the literature. South Med J 2009; 102:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/15\">",
"      Byers RJ, Marshall DA, Freemont AJ. Pericardial involvement in systemic sclerosis. Ann Rheum Dis 1997; 56:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/16\">",
"      Meune C, Vignaux O, Kahan A, Allanore Y. Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch Cardiovasc Dis 2010; 103:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/17\">",
"      Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/18\">",
"      Bazzani C, Cavazzana I, Ceribelli A, et al. Cardiological features in idiopathic inflammatory myopathies. J Cardiovasc Med (Hagerstown) 2010; 11:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/19\">",
"      Lundberg IE. Cardiac involvement in autoimmune myositis and mixed connective tissue disease. Lupus 2005; 14:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/20\">",
"      Gy&ouml;ngy&ouml;si M, Pokorny G, Jambrik Z, et al. Cardiac manifestations in primary Sj&ouml;gren's syndrome. Ann Rheum Dis 1996; 55:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/21\">",
"      Wyplosz B, Marijon E, Dougados J, Pouchot J. Sarcoidosis: an unusual cause of acute pericarditis. Acta Cardiol 2010; 65:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/22\">",
"      Narita H, Ohte N, Yoneyama A, et al. Takayasu's arteritis accompanied with massive pericardial effusion--a case report. Angiology 1999; 50:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/23\">",
"      Li JJ, Fang CH, Chen MZ, Chen X. Takayasu's arteritis accompanied with pericarditis: a case report. Cardiology 2004; 102:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/24\">",
"      Guillaume M, Vachiery F, Cogan E. Pericarditis: an unusual manifestation of giant cell arteritis. Am J Med 1991; 91:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/25\">",
"      Gonzalez-Gay MA, Martinez-Dubois C, Agudo M, et al. Giant cell arteritis: epidemiology, diagnosis, and management. Curr Rheumatol Rep 2010; 12:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/26\">",
"      Blot M, Gu&eacute;pet H, Aubriot-Lorton MH, et al. An atypical case of giant cell arteritis (Horton's disease) associated with facial swelling, confusion, and pericarditis in an elderly woman. J Am Geriatr Soc 2010; 58:2040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/27\">",
"      Cullen S, Duff DF, Denham B, Ward OC. Cardiovascular manifestations in Kawasaki disease. Ir J Med Sci 1989; 158:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/28\">",
"      Agard C, Rendu E, Leguern V, et al. Churg-Strauss syndrome revealed by granulomatous acute pericarditis: two case reports and a review of the literature. Semin Arthritis Rheum 2007; 36:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/29\">",
"      Korantzopoulos P, Papaioannides D, Siogas K. The heart in Wegener's granulomatosis. Cardiology 2004; 102:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/30\">",
"      Baldini C, Talarico R, Della Rossa A, Bombardieri S. Clinical manifestations and treatment of Churg-Strauss syndrome. Rheum Dis Clin North Am 2010; 36:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/31\">",
"      Atzeni F, Sarzi-Puttini P, Doria A, et al. Beh&ccedil;et's disease and cardiovascular involvement. Lupus 2005; 14:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/32\">",
"      Rigante D, Cantarini L, Imazio M, et al. Autoinflammatory diseases and cardiovascular manifestations. Ann Med 2011; 43:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/33\">",
"      Kees S, Langevitz P, Zemer D, et al. Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). QJM 1997; 90:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/34\">",
"      Okutur K, Seber S, Oztekin E, et al. Recurrent pericarditis as the initial manifestation of Familial Mediterranean fever. Med Sci Monit 2008; 14:CS139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/35\">",
"      Cantarini L, Lucherini OM, Cimaz R, et al. Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome. Int J Immunopathol Pharmacol 2009; 22:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2568/abstract/36\">",
"      Cantarini L, Lucherini OM, Baldari CT, et al. Familial clustering of recurrent pericarditis may disclose tumour necrosis factor receptor-associated periodic syndrome. Clin Exp Rheumatol 2010; 28:405.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16578 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-D7E3B57AC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_32_2568=[""].join("\n");
var outline_f2_32_2568=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1817492\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1817334\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H814260\">",
"      CLINICAL PRESENTATION, DIAGNOSIS, AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H814268\">",
"      SPECIFIC SYSTEMIC INFLAMMATORY DISEASES WITH PERICARDIAL INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1817357\">",
"      Connective tissue diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1817364\">",
"      - Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1817371\">",
"      - Rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1817378\">",
"      - Adult Still's disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1817437\">",
"      - Systemic sclerosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1817430\">",
"      - Dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1817423\">",
"      - Mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1817416\">",
"      - Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1817393\">",
"      Other disease entities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1817401\">",
"      - Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H771997\">",
"      - Pericarditis in acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H340783\">",
"      - Vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H340998\">",
"      Beh&ccedil;et's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1817385\">",
"      AUTOINFLAMMATORY DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H341116\">",
"      Familial Mediterranean Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H341124\">",
"      Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1817492\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/16578\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/16578|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/53/35675\" title=\"table 1\">",
"      Systemic autoimmune diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/35/41532\" title=\"table 2\">",
"      Drug therapy in acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/26/17836\" title=\"table 3\">",
"      Pericardial involvement in connective tissue and other diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/61/37852\" title=\"table 4\">",
"      Cardiac involvement in vasculitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=related_link\">",
"      Cardiac sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=related_link\">",
"      Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/3/11320?source=related_link\">",
"      Clinical manifestations and diagnosis of adult Still's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=related_link\">",
"      Clinical manifestations and diagnosis of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43401?source=related_link\">",
"      Clinical manifestations of mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=related_link\">",
"      Clinical presentation and diagnostic evaluation of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=related_link\">",
"      Diagnosis and treatment of pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22456?source=related_link\">",
"      Non-coronary cardiac manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11177?source=related_link\">",
"      Recurrent pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/44/713?source=related_link\">",
"      Treatment of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28551?source=related_link\">",
"      Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_32_2569="Distal pancreatectomy: Techniques";
var content_f2_32_2569=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Distal pancreatectomy: Techniques",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/32/2569/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/32/2569/contributors\">",
"     Timothy R Donahue, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/32/2569/contributors\">",
"     Oscar Joe Hines, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/32/2569/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/32/2569/contributors\">",
"     Stanley W Ashley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/32/2569/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/32/2569/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/32/2569/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal pancreatectomy or pancreatic tail resection is the resection of pancreatic tissue to the left of the superior mesenteric artery and vein. This procedure was first performed by Billroth in 1884 and accounts for approximately one quarter of all pancreatic resections.",
"   </p>",
"   <p>",
"    Please note that technical details such as suture choice presented below reflect the author's preferences and are not meant to imply that these are requirements for successful surgical outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal pancreatectomy is performed primarily for malignant and premalignant diseases including pancreatic adenocarcinoma, pancreatic cystic neoplasms, and neuroendocrine tumors. Benign indications for distal pancreatectomy include chronic pancreatitis, pancreatic pseudocysts, and trauma with main pancreatic ductal disruption. In a series of 232 distal pancreatectomies where 164 were performed for pancreas-specific disease, 84 percent were for malignant or premalignant disease, while only 16 percent were for benign diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Adenocarcinoma in body and tail of the pancreas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with adenocarcinoma in the body and tail of the gland have historically presented with more advanced disease because lesions in this area can become quite large before they become symptomatic from local invasion and metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. As a result of this later presentation, body and tail lesions are less likely to be resectable and have been associated with shorter survival than pancreatic head cancers, although the biology of the tumors is the same. However, improved high resolution pancreatic-protocol computed tomography (CT) and magnetic resonance (MR) imaging techniques have led to the more frequent recognition of body and tail lesions at earlier stages. Thus, distal pancreatectomy is becoming a more frequently used procedure.",
"   </p>",
"   <p>",
"    Even if preoperative imaging shows potentially resectable disease, many surgeons believe that laparoscopic exploration should precede attempted resection, since a significant proportion will have occult peritoneal metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Staging laparoscopy has been shown to alter the management approach in up to 44 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/7\">",
"     7",
"    </a>",
"    ]. Splenectomy should be anticipated to ensure clear margins and adequate lymph node sampling [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\", section on 'Diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neuroendocrine tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroendocrine tumors within the body and tail of the gland may be resected or enucleated depending on the size and the relationship of the tumor to the pancreatic duct [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/9\">",
"     9",
"    </a>",
"    ]. Nonfunctioning tumors that are large, suspicious for malignancy, or intimately associated with the main pancreatic duct should be resected rather than enucleated because of a high risk of a postoperative fistula with enucleation in these settings [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is ongoing debate regarding the resection of a primary malignant neuroendocrine tumor in the face of metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Resection is generally considered if the primary site tumor is causing symptoms, or if the primary and liver metastases are both amenable to potentially curative resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691413#H691413\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Management of the primary site in patients with metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Premalignant and cystic neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic neoplasms for which distal pancreatectomy may be indicated include mucinous cystic neoplasms (MCN), serous cystadenoma, solid pseudopapillary neoplasm (also called papillary cystic neoplasms), and intraductal papillary mucinous neoplasms (IPMN). MCN and solid pseudopapillary neoplasms are most commonly located in the body and tail of the gland; serous cystadenomas have equal distribution throughout the gland; and IPMN (both main duct and branch duct types) are primarily located in the head of the gland. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=see_link\">",
"     \"Pathology of exocrine pancreatic neoplasms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15686?source=see_link\">",
"     \"Classification of pancreatic cysts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3368?source=see_link\">",
"     \"Pancreatic cystic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Until premalignant and benign lesions can reliably be differentiated from malignant cystic neoplasms, most experts argue that cysts suspicious for malignancy should be resected [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. For IPMN lesions in the body and tail, proposed criteria (the Sendai Consensus Guidelines) (",
"    <a class=\"graphic graphic_table graphicRef53511 \" href=\"UTD.htm?14/45/15067\">",
"     table 1",
"    </a>",
"    ) for pancreatic resection are the presence of &ge;1 of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptoms attributable to the cyst (eg, pancreatitis)",
"     </li>",
"     <li>",
"      Dilation of the main pancreatic duct (&ge;10 mm)",
"     </li>",
"     <li>",
"      Cyst size &ge;30 mm",
"     </li>",
"     <li>",
"      Presence of intramural nodules",
"     </li>",
"     <li>",
"      Cyst fluid cytology suspicious or positive for malignancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria continue to evolve as the natural history of these lesions is better defined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3368?source=see_link&amp;anchor=H18#H18\">",
"     \"Pancreatic cystic neoplasms\", section on 'Malignant potential and management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=see_link&amp;anchor=H5510679#H5510679\">",
"     \"Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pseudocysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudocysts are non-epithelialized fluid collections of pancreatic fluid that develop at least four to six weeks after the onset of an episode of acute pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/15\">",
"     15",
"    </a>",
"    ]. Indications for treatment include rapidly enlarging or symptomatic cysts. Treatment options include external drainage, endoscopic drainage, internal surgical drainage, or resection, including distal pancreatectomy. Distal pancreatectomy is usually reserved for cases where there has been significant compromise of an adjacent structure, there is a disruption of the main pancreatic duct,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    if pancreatic ductal disruption persists despite stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17928?source=see_link\">",
"     \"Diagnosis and management of pseudocysts of the pancreas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chronic pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal pancreatectomy is rarely used for the management of chronic pancreatitis. Most often, the entire gland is involved and pain relief appears greatest with resections of the head of the gland rather than the tail [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/16\">",
"     16",
"    </a>",
"    ]. Results of distal pancreatectomy for chronic pancreatitis are mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The uncertain yield of pain relief must be matched with the potential of new-onset diabetes mellitus, which in some series is as high as 20 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35572?source=see_link\">",
"     \"Complications of chronic pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31369?source=see_link\">",
"     \"Treatment of chronic pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal pancreatectomy is indicated in trauma patients where the main pancreatic duct is disrupted. This injury most commonly occurs after blunt trauma in which the pancreas is crushed against the vertebral bodies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preoperative evaluation will depend on the indication for surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preoperative evaluation, for all indications, should begin with a high resolution pancreatic protocol CT scan that includes a precisely-timed intravenous (IV) contrast infusion to enhance the pancreatic parenchyma and surrounding vessels. Following the injection of IV contrast, 2 to 3 mm images of the pancreas are obtained during the \"pancreatic arterial phase\" and then 5 mm images are later captured during the \"venous phase.\" During the pancreatic phase, the pancreatic parenchyma, celiac axis, and superior mesenteric artery are enhanced with contrast, while the venous phase includes the superior mesenteric vein, portal vein, and splenic vein. If the institution does not have a well-established pancreas CT protocol, then high resolution CT with IV contrast should be sufficient.",
"   </p>",
"   <p>",
"    Some surgeons prefer a magnetic resonance cholangiopancreatogram (MRCP) instead of a pancreas protocol or high-resolution CT scan. MRCP is more precise at imaging the relation of the mass or cyst to the main pancreatic duct, but can be more difficult to read. Endoscopic ultrasound (EUS) can also provide detailed information about solid masses and cyst characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/21\">",
"     21",
"    </a>",
"    ]. Endoscopic retrograde cholangiopancreatogram (ERCP) is usually done at the same time as EUS, but usually isn't necessary as an additional test. ERCP can provide detailed information of the main pancreatic duct and its relation to the mass or cyst, but sufficient information is usually obtained from CT or MRCP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1929?source=see_link\">",
"     \"Endoscopic ultrasound in the staging of exocrine pancreatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29591?source=see_link\">",
"     \"Endoscopic ultrasound in chronic pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in whom splenectomy is planned should receive preoperative vaccination for splenectomy 14 days prior to surgery. If vaccination is not possible preoperatively, then it should be given after the 14th postoperative day to maximize opsonophagocytic function. The current vaccine recommendations include immunization with pneumococcal, meningococcal, and conjugated H. influenza type b vaccines.",
"   </p>",
"   <p>",
"    We routinely vaccinate all patients when distal pancreatectomy is planned or likely. These patients include those with pancreatic tail cysts or masses that are biopsy proven or highly suspicious for cancer and those in whom salvaging the spleen does not appear to be technically possible, such as when lesions involve the splenic vessels, the cysts or tumors are large, or there is significant inflammation obscuring the border of the pancreatic body and distal pancreas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Informed consent obtained prior to surgery should include the possibility of splenectomy.",
"   </p>",
"   <p>",
"    Other potential complications and postoperative sequelae of which the patient should be made aware include new-onset insulin-dependent diabetes mellitus (8 to 9 percent), pancreatic fistula (5 percent), intraabdominal abscess (4 percent), small bowel obstruction (4 percent), and postoperative bleeding (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/19,22\">",
"     19,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a trend towards an increased risk of new onset diabetes in patients with chronic pancreatitis as compared to patients who undergo distal pancreatectomy for other indications (9 versus 7.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35572?source=see_link\">",
"     \"Complications of chronic pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31369?source=see_link\">",
"     \"Treatment of chronic pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should receive prophylactic antibiotics within a one hour \"window\" before the initial incision [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. For biliary tract surgery, prophylaxis is recommended in patients at high risk for infection, defined as age greater than 70 years, acute cholecystitis, a nonfunctioning gallbladder, obstructive jaundice, and common bile duct stones. The recommended antibiotics are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (1 to 2 g IV) or, in patients allergic to penicillins and cephalosporins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    plus one of the following:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SURGEON'S SAFETY CHECKLIST FOR DISTAL PANCREATECTOMY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Consent includes possibility of splenectomy, new-onset diabetes, pancreatic fistula, intraabdominal abscess, small bowel obstruction, and postoperative bleeding",
"     </li>",
"     <li>",
"      Vaccination has been given if splenectomy is anticipated",
"     </li>",
"     <li>",
"      Patient has been typed and crossed in case blood loss necessitates transfusion",
"     </li>",
"     <li>",
"      Anesthetic concerns specific to the patient have been reviewed",
"     </li>",
"     <li>",
"      Proper staplers and drains are available",
"     </li>",
"     <li>",
"      Prophylactic antibiotics have been administered",
"     </li>",
"     <li>",
"      Imaging studies have been reviewed and are displayed in the operating room",
"     </li>",
"     <li>",
"      Appropriate deep venous thromboembolism (DVT) prophylaxis has been ordered",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SURGICAL TECHNIQUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Open operation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The steps for a retrograde distal pancreatectomy with splenectomy include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Patient positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should be placed in a supine or partially right lateral decubitus position with the left side up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Initial exploration",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the indication for operation is an adenocarcinoma, a staging laparoscopy may be performed to minimize the number of cases where the cancer appears resectable on preoperative imaging studies but on laparotomy is discovered to be unresectable due to metastatic disease or local invasion.",
"   </p>",
"   <p>",
"    To perform a staging laparoscopy, a 10 mm periumbilical trocar for the camera and one to two 5 mm working trocars are inserted for atraumatic graspers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biopsy forceps. The liver surface and peritoneum are first inspected for distant disease. Metastases less than one centimeter in diameter on the surface of the liver and peritoneum are rarely detected by preoperative imaging techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If any suspicious nodules are identified, a biopsy is taken and sent for frozen section. Next, the transverse colon is lifted anteriorly to inspect the mesocolon for direct extension. The gastrocolic ligament can then be opened to explore the lesser sac, although this is rarely performed for diagnostic purposes. The ultrasound probe with Doppler can be used to evaluate for vascular involvement, a technique that is more applicable and particularly useful for periampullary tumors where vascular involvement frequently determines respectability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link&amp;anchor=H1618421#H1618421\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\", section on 'Staging laparoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If there is no evidence of unresectability on laparoscopy, the open operation is begun. A left upper quadrant subcostal incision that extends over the midline to the right is most commonly used. Alternatively, a midline incision may be suitable in thin patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link&amp;anchor=H1618421#H1618421\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\", section on 'Staging laparoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the indication for the operation is cancer, or a mass or cyst that is suspicious for cancer, the abdomen is first thoroughly explored to identify distant disease or carcinomatosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Dissection and mobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lesser sac is entered by taking the omentum off of the transverse colon. This dissection should be extended from the splenic flexure to the hepatic flexure in order to ensure that there is a clear view of the pancreas from the duodenum to the spleen. The posterior stomach is then dissected free of the anterior aspect of the pancreas. The stomach and pancreas are usually easily separated, but prior episodes of pancreatitis can generate adhesions and complicate dissection. The anterior surface of the entire gland can then be palpated in an attempt to identify the lesion (",
"    <a class=\"graphic graphic_figure graphicRef60042 \" href=\"UTD.htm?7/33/7703\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The body and tail are next mobilized by first incising the peritoneum along the inferior border of the pancreas while paying particular attention to the location of the inferior mesenteric vein (IMV). The peritoneum overlying the superior border is then opened just above the level of the splenic artery. Now the surgeon can circumferentially palpate the body and tail of the gland. If the lesion is not palpable at this point, intraoperative ultrasound should be used, if available.",
"   </p>",
"   <p>",
"    If a splenectomy is part of the planned procedure, it is best to ligate the splenic artery and vein near their origins in order to prevent later blood loss. The gastrosplenic ligament including the short gastric vessels is then ligated. If the spleen will be preserved, we prefer to take only half of the short gastric vessels in case the splenic vein must be sacrificed during the pancreatectomy.",
"   </p>",
"   <p>",
"    The splenic flexure of the colon is mobilized and rotated in a medial and inferior direction. The splenorenal ligament is divided. The lateral peritoneal attachments of the spleen are incised. Now the spleen and distal pancreas are freed and can be mobilized in a lateral to medial direction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Transection and closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pancreas may be divided at the level of the superior mesenteric vein or at a place the surgeon deems appropriate to ensure a negative margin. The gland is transected with a thoracic (TA) stapler using 3.5 or 4.5 mm staples (",
"    <a class=\"graphic graphic_figure graphicRef74555 \" href=\"UTD.htm?31/22/32100\">",
"     figure 2",
"    </a>",
"    ). A frozen section of the cut end of the pancreatic specimen should be obtained to be certain it is negative for malignancy or high grade dysplasia.",
"   </p>",
"   <p>",
"    The best method to transect the pancreas and close the pancreatic remnant to prevent a leak has not been identified. As a result, there are numerous techniques that have been employed. Options for closure include a stapled versus a hand-sewn technique, creation of a pancreaticoenteric anastomosis, placement of a seromuscular patch, ultrasonic dissection, reinforcement with mesh, and the use of fibrin glue seal. Although a meta-analysis found a trend toward a lower leak rate with stapled closure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/26\">",
"     26",
"    </a>",
"    ], a subsequent randomized trial of stapled (177 patients) versus handsewn closure (175 patients) after distal pancreatectomy (DISPACT [DIStal PAnCreaTectomy] trial) showed no difference in the pancreatic fistula rate between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The authors prefer the stapled technique with 4.5 mm staples and a 3-0 prolene U-stitch with nonabsorbable suture at the level of the pancreatic duct. This is usually on the posterior aspect of the gland, one-third of the distance from the superior border.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Drains",
"    </span>",
"    &nbsp;&mdash;&nbsp;After hemostasis is confirmed a large closed suction drain is placed adjacent to the cut edge of the pancreas to control for any potential leak.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Splenic preservation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of splenic preservation should be considered on a case-by-case fashion. The possibility of splenic preservation was first introduced by Mallet-Guy and Vachon in 1943 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/28\">",
"     28",
"    </a>",
"    ]. Some series demonstrate benefits to splenic preservation, including lower perioperative infectious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/29\">",
"     29",
"    </a>",
"    ] and a lower fistula rate [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/1\">",
"     1",
"    </a>",
"    ], although others did not demonstrate a benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In general, a splenectomy should be performed to provide a clear margin negative resection (R0) and ensure sampling of at least 15 regional lymph nodes when operating for a lesion that is highly suspicious for a cancer (",
"    <a class=\"graphic graphic_figure graphicRef64624 \" href=\"UTD.htm?33/19/34101\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Radical antegrade modular pancreaticosplenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radical antegrade modular pancreaticosplenectomy (RAMPS) procedure is an alternative open operative approach to the above described retrograde distal pancreatectomy and splenectomy for adenocarcinoma of the body and tail of the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/32\">",
"     32",
"    </a>",
"    ]. This dissection includes early division of the neck of the pancreas and splenic vessels and a celiac node dissection. The plane of dissection then runs posteriorly along the superior mesenteric artery and celiac artery to the level of the aorta and then laterally to the adrenal. A series of 23 patients with pancreatic cancer treated with the RAMPS procedure demonstrated that 91 percent had negative tangential margins [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/33\">",
"     33",
"    </a>",
"    ]. The authors assert that this modified technique can achieve a high rate of negative posterior resection margins and sampling of regional lymph nodes with little morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Laparoscopic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;As surgeons become more comfortable with laparoscopic distal pancreatectomy, its role has been expanding. It was first performed in 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/34\">",
"     34",
"    </a>",
"    ], and by 2006, there were over 400 reported cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most authors still advocate an open operation for cases where the concern for malignancy is high [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. There are few long-term data comparing laparoscopic to open resections for cancer; thus, most surgeons continue to perform laparoscopic resections for benign or premalignant indications only. Common disadvantages with laparoscopic distal pancreatectomy include technical difficulties, inability to manually palpate the gland and to appreciate the extent of a cyst or mass, the potential inability to reinforce the stapled pancreatic duct stump with suture, the potential inability to obtain sufficient negative margins in cancer resections, and the extent of the lymph node harvest for cancer cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. It may also be more difficult to preserve the spleen.",
"   </p>",
"   <p>",
"    Since 2005, there have been many small case series that reported on the technical feasibility and success of laparoscopic distal pancreatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/34,35,38-40\">",
"     34,35,38-40",
"    </a>",
"    ]. For example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 2005 European Multicenter Laparoscopic Pancreas Study is the largest series and included 25 centers and 97 distal pancreatectomies [",
"      <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/34\">",
"       34",
"      </a>",
"      ]. This study confirmed the safety of laparoscopic distal pancreatectomy and splenectomy, but questioned the laparoscopic approach for malignant disease. During a median follow-up of 15 months, 23 percent of patients with pancreatic malignancies had tumor recurrence.",
"     </li>",
"     <li>",
"      A large single institution series reported on 123 patients who underwent laparoscopic distal pancreatectomy and splenectomy; 39 had premalignant neoplastic cysts, 43 had neuroendocrine tumors, and 13 had adenocarcinomas [",
"      <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/41\">",
"       41",
"      </a>",
"      ]. The median survival for patients with ductal adenocarcinoma was 14 months, which is similar to reports for the open approach.",
"     </li>",
"     <li>",
"      In addition, a small case-matched retrospective report of 15 patients confirmed that patients who underwent a laparoscopic resection had a decreased length of stay and faster return to normal activity as compared to patients who had an open procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/42\">",
"       42",
"      </a>",
"      ]. In this report, the pancreatic leak rate and overall complication rates were similar for the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Theoretical advantages to the laparoscopic approach include less perioperative pain, smaller incisions, a reduced hospital stay, and a faster postoperative recovery. The primary concern is a potential increased risk of a pancreatic fistula since it may be more difficult to reliably secure the pancreatic transection with staples or suture reinforcement. To date, there have not been any randomized trials to compare rate of postoperative fistula between the open and laparoscopic approach.",
"   </p>",
"   <p>",
"    A detailed description of the procedure is as follows:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Patient positioning for laparoscopic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should be placed in a supine position. The surgeon stands to the right side and the assistant to the left side of the patient. Alternatively, some surgeons prefer to have the legs apart such that the operating surgeon can stand between the legs. The patient is rotated 30 to 45 degrees to the right and placed in reverse Trendelenburg position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Trocar placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 11 mm trocar is placed to the left of the umbilicus as the camera port (",
"    <a class=\"graphic graphic_figure graphicRef69664 \" href=\"UTD.htm?19/41/20115\">",
"     figure 4",
"    </a>",
"    ). An additional left-sided 5 mm trocar is placed between the left anterior axillary line and midclavicular line just cephalad to the umbilicus as a working port. On the right side, a 12 mm trocar is placed opposite the 10 mm port and used for the harmonic scalpel and endoscopic gastrointestinal anastomosis stapler (endoGIA). A 5 mm trocar working port is placed opposite the left-sided 5 mm port. A final 5 mm trocar is placed in the subxiphoid area for a stomach and liver retractor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Laparoscopic approach for dissection and mobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the dissection in the operation can be completed with a harmonic scalpel (5 mm) and the occasional use of cautery. The first step, as in the open operation, is to take the omentum off of the transverse colon from the hepatic flexure to splenic flexure. It is efficient to continue cephalad taking the gastrosplenic ligament with the short gastric vessels all the way to the diaphragm. If the spleen will be preserved, we prefer to take only half of the short gastric vessels in case the splenic vein must be sacrificed during the pancreatectomy. Now with the lesser sac exposed, the posterior aspect of the stomach should be freed from the anterior surface of the pancreas.",
"   </p>",
"   <p>",
"    In order to retract the colon medially and inferiorly, the splenic flexure should next be mobilized. The ultrasound probe should be used on the anterior aspect of the pancreas in order to identify the lesion and delineate the proximal extent of resection.",
"   </p>",
"   <p>",
"    The surgeon then incises the peritoneum along the inferior and superior borders of the pancreas, paying particular attention on the superior border to identify and isolate the splenic artery in a cephalad direction away from the pancreas. On the undersurface of the gland, the splenic vein is identified and gently dissected off of the pancreas, creating a window for the introduction of the stapler.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Laparoscopic approach for transection and closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gland is then transected with a blue load (3.5 mm) of an endoGIA stapler. If the spleen is to be preserved, the gland is then dissected off the vessels medial to lateral with the harmonic scalpel. Otherwise, the splenic artery is clipped and incised, and the vein separately incised with a vascular endoGIA.",
"   </p>",
"   <p>",
"    If a splenectomy is planned, the lateral attachments of the spleen, the splenorenal ligament, and the splenocolic ligament should next be completely freed, such that the spleen becomes mobile and can be retracted medially. This step should be reserved until later, so the spleen does not become freely mobile and in the way of the dissection.",
"   </p>",
"   <p>",
"    The specimen should then be freely mobile and placed in a specimen bag that can be extracted through an extension of one of the trocar port sites. A #19 round Jackson-Pratt or Blake closed suction drain at the cut end of the pancreas is placed before the removal of the trocars.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Alternative approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many alternative laparoscopic approaches; the most common is a medial to lateral resection, where the splenic vessels and pancreas are transected first and then the rest of the gland and spleen are freed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine postoperative management is primarily focused on return of bowel function and management of closed suction drain output. Average length of stay after the laparoscopic procedure is five days versus seven days after the open operation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     MORBIDITY AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The operative mortality rate of all types of pancreatic resections at high-volume centers has decreased to less than 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/43\">",
"     43",
"    </a>",
"    ], but the morbidity has largely not changed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morbidity after distal pancreatectomy is primarily from development of a leak and pancreatic fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/44\">",
"     44",
"    </a>",
"    ]. Whether a fistula develops after a distal pancreatectomy depends in part on the underlying disease state of the gland (ie, the incidence is lower for chronic pancreatitis where the gland is fibrotic as compared with cases for benign cysts where the gland tends to be much softer) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/45\">",
"     45",
"    </a>",
"    ]. A study of the costs incurred by postoperative pancreatic fistulas concluded that these complications significantly increase the hospital stay and cost [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pancreatic fistulas are diagnosed when the fluid output through an operatively or percutaneously placed drain has an amylase content greater than three times the upper normal serum value [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/47\">",
"     47",
"    </a>",
"    ]. The reported incidence of pancreatic fistulas after distal pancreatectomy is 0 to 64 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This wide range is primarily due to use of different definitions. For this reason, the International Study Group on Pancreatic Fistulas (ISGPF) has established a strict definition in an attempt to normalize the data [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/48\">",
"     48",
"    </a>",
"    ]. The official definition from the ISGPF is a drain output of any measurable volume of fluid on or after postoperative day 3 with an amylase content greater than 3 times the serum amylase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28903?source=see_link\">",
"     \"Clinical features, diagnosis, and prevention of pancreatic fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The routine use of somatostatin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (a long acting somatostatin analogue) to prevent fistulas has been examined. Somatostatin reduces pancreatic, gastric, and enteric secretions and theoretically would be helpful for reducing postoperative fistula formation, but the data are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/47\">",
"     47",
"    </a>",
"    ]. A meta-analysis of postoperative somatostatin found that it did decrease pancreas-specific complications, but when the subgroup of patients who had a distal pancreatectomy was examined, there was no statistical difference in pancreas-specific complications [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not routinely use prophylactic somatostatin, although, in our experience, somatostatin has been helpful in selected patients with high output fistulas to control volume output. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/29/4567?source=see_link\">",
"     \"Physiology of somatostatin and its analogues\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Seamguard, a bioabsorbable staple line-reinforcement product has been investigated in several small nonrandomized studies for the prevention of leaks and fistulas after distal pancreatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. In the largest single institution study of 85 patients undergoing distal pancreatectomy there was a 4 percent leak rate in patients who had staple resection using Seamguard reinforcement as compared with a 26 percent leak rate in patients who had suture ligation of the pancreatic duct or nonreinforced staple resection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/50\">",
"     50",
"    </a>",
"    ]. However, this technique can not be applied in all situations; as thick or fibrotic pancreases may be very difficult to close with a stapler. Omental flaps and falciform ligament reinforcements have also been employed. &nbsp;These procedures will require more study before they can be recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?2/32/2569/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distal or left pancreatectomy involves resecting all the pancreatic parenchyma to the left of the superior mesenteric vessels. This procedure can be used for both benign and malignant diseases and may be performed either open or laparoscopically. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A pancreatic-protocol computed tomography (CT) scan with intravenous contrast is an important component of the preoperative work-up of pancreatic disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An open operation is advocated for malignant lesions to assure sufficient margins and adequate lymph node harvest.",
"     </li>",
"     <li>",
"      For malignant disease, splenectomy should be performed to ensure better local control and peripancreatic lymph node sampling. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Informed consent for a distal pancreatectomy should include the possibility of splenectomy and the need for preoperative vaccination. Other important risks and potential complications to discuss with the patient include new onset insulin dependent diabetes, pancreatic leak or fistula, intra-abdominal abscess, small bowel obstruction, and bleeding. Risks may be higher in patients with chronic pancreatitis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Informed consent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the indication for operation is an adenocarcinoma, staging laparoscopy to look for peritoneal or liver metastases should be done before open operation is undertaken. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Initial exploration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Somatostatin may help lower the volume of high-output pancreatic fistulas. The routine use of prophylactic postoperative somatostatin does not decrease pancreas-specific complications. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Postoperative management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/1\">",
"      Goh BK, Tan YM, Chung YF, et al. Critical appraisal of 232 consecutive distal pancreatectomies with emphasis on risk factors, outcome, and management of the postoperative pancreatic fistula: a 21-year experience at a single institution. Arch Surg 2008; 143:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/2\">",
"      Wade TP, Virgo KS, Johnson FE. Distal pancreatectomy for cancer: results in U.S. Department of Veterans Affairs hospitals, 1987-1991. Pancreas 1995; 11:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/3\">",
"      Brennan MF, Moccia RD, Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas. Ann Surg 1996; 223:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/4\">",
"      Brennan MF, Kattan MW, Klimstra D, Conlon K. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg 2004; 240:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/5\">",
"      Fern&aacute;ndez-del Castillo C, Warshaw AL. Laparoscopy for staging in pancreatic carcinoma. Surg Oncol 1993; 2 Suppl 1:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/6\">",
"      del Castillo CF, Warshaw L. Peritoneal metastases in pancreatic carcinoma. Hepatogastroenterology 1993; 40:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/7\">",
"      Doucas H, Sutton CD, Zimmerman A, et al. Assessment of pancreatic malignancy with laparoscopy and intraoperative ultrasound. Surg Endosc 2007; 21:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/8\">",
"      Tomlinson JS, Jain S, Bentrem DJ, et al. Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg 2007; 142:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/9\">",
"      Norton JA. Surgery for primary pancreatic neuroendocrine tumors. J Gastrointest Surg 2006; 10:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/10\">",
"      Kazanjian KK, Reber HA, Hines OJ. Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 2006; 141:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/11\">",
"      Hung JS, Chang MC, Lee PH, Tien YW. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases? World J Surg 2007; 31:2392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/12\">",
"      Kiely JM, Nakeeb A, Komorowski RA, et al. Cystic pancreatic neoplasms: enucleate or resect? J Gastrointest Surg 2003; 7:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/13\">",
"      Talamini MA, Moesinger R, Yeo CJ, et al. Cystadenomas of the pancreas: is enucleation an adequate operation? Ann Surg 1998; 227:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/14\">",
"      Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006; 6:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/15\">",
"      Nealon WH, Walser E. Surgical management of complications associated with percutaneous and/or endoscopic management of pseudocyst of the pancreas. Ann Surg 2005; 241:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/16\">",
"      Kondo Y, Friess H, Tempia-Caliera AA, B&uuml;chler MW. Duodenum-preserving pancreatic head resection: future standard operation in chronic pancreatitis. Swiss Surg 2000; 6:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/17\">",
"      Rattner DW, Fernandez-del Castillo C, Warshaw AL. Pitfalls of distal pancreatectomy for relief of pain in chronic pancreatitis. Am J Surg 1996; 171:142.",
"     </a>",
"    </li>",
"    <li>",
"     Maingot's abdominal operations, Maingot, R, Zinner, M (Eds), Appleton &amp; Lange, Connecticut 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/19\">",
"      King J, Kazanjian K, Matsumoto J, et al. Distal pancreatectomy: incidence of postoperative diabetes. J Gastrointest Surg 2008; 12:1548.",
"     </a>",
"    </li>",
"    <li>",
"     Feliciano DV, Mattox KL, Moore EE. Trauma, McGraw-Hill, New York 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/21\">",
"      Kubo H, Chijiiwa Y, Akahoshi K, et al. Intraductal papillary-mucinous tumors of the pancreas: differential diagnosis between benign and malignant tumors by endoscopic ultrasonography. Am J Gastroenterol 2001; 96:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/22\">",
"      Lillemoe KD, Kaushal S, Cameron JL, et al. Distal pancreatectomy: indications and outcomes in 235 patients. Ann Surg 1999; 229:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/23\">",
"      Fry DE. Surgical site infections and the surgical care improvement project (SCIP): evolution of national quality measures. Surg Infect (Larchmt) 2008; 9:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/24\">",
"      Bratzler DW, Houck PM, Surgical Infection Prevention Guidelines Writers Workgroup, et al. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004; 38:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/25\">",
"      John TG, Greig JD, Crosbie JL, et al. Superior staging of liver tumors with laparoscopy and laparoscopic ultrasound. Ann Surg 1994; 220:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/26\">",
"      Knaebel HP, Diener MK, Wente MN, et al. Systematic review and meta-analysis of technique for closure of the pancreatic remnant after distal pancreatectomy. Br J Surg 2005; 92:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/27\">",
"      Diener MK, Seiler CM, Rossion I, et al. Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. Lancet 2011; 377:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/28\">",
"      MALLET-GUY P, VACHON A. [Not Available]. Lyon Chir 1950; 45:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/29\">",
"      Shoup M, Brennan MF, McWhite K, et al. The value of splenic preservation with distal pancreatectomy. Arch Surg 2002; 137:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/30\">",
"      Aldridge MC, Williamson RC. Distal pancreatectomy with and without splenectomy. Br J Surg 1991; 78:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/31\">",
"      Benoist S, Dugu&eacute; L, Sauvanet A, et al. Is there a role of preservation of the spleen in distal pancreatectomy? J Am Coll Surg 1999; 188:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/32\">",
"      Strasberg SM, Drebin JA, Linehan D. Radical antegrade modular pancreatosplenectomy. Surgery 2003; 133:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/33\">",
"      Strasberg SM, Linehan DC, Hawkins WG. Radical antegrade modular pancreatosplenectomy procedure for adenocarcinoma of the body and tail of the pancreas: ability to obtain negative tangential margins. J Am Coll Surg 2007; 204:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/34\">",
"      Mabrut JY, Fernandez-Cruz L, Azagra JS, et al. Laparoscopic pancreatic resection: results of a multicenter European study of 127 patients. Surgery 2005; 137:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/35\">",
"      Ammori BJ, Baghdadi S. Minimally invasive pancreatic surgery: the new frontier? Curr Gastroenterol Rep 2006; 8:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/36\">",
"      Ammori BJ. Pancreatic surgery in the laparoscopic era. JOP 2003; 4:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/37\">",
"      Underwood RA, Soper NJ. Current status of laparoscopic surgery of the pancreas. J Hepatobiliary Pancreat Surg 1999; 6:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/38\">",
"      Pierce RA, Spitler JA, Hawkins WG, et al. Outcomes analysis of laparoscopic resection of pancreatic neoplasms. Surg Endosc 2007; 21:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/39\">",
"      Palanivelu C, Shetty R, Jani K, et al. Laparoscopic distal pancreatectomy: results of a prospective non-randomized study from a tertiary center. Surg Endosc 2007; 21:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/40\">",
"      Root J, Nguyen N, Jones B, et al. Laparoscopic distal pancreatic resection. Am Surg 2005; 71:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/41\">",
"      Fern&aacute;ndez-Cruz L, Cosa R, Blanco L, et al. Curative laparoscopic resection for pancreatic neoplasms: a critical analysis from a single institution. J Gastrointest Surg 2007; 11:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/42\">",
"      Velanovich V. Case-control comparison of laparoscopic versus open distal pancreatectomy. J Gastrointest Surg 2006; 10:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/43\">",
"      Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/44\">",
"      Kleeff J, Diener MK, Z'graggen K, et al. Distal pancreatectomy: risk factors for surgical failure in 302 consecutive cases. Ann Surg 2007; 245:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/45\">",
"      Diener MK, Knaebel HP, Witte ST, et al. DISPACT trial: a randomized controlled trial to compare two different surgical techniques of DIStal PAnCreaTectomy - study rationale and design. Clin Trials 2008; 5:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/46\">",
"      Rodr&iacute;guez JR, Germes SS, Pandharipande PV, et al. Implications and cost of pancreatic leak following distal pancreatic resection. Arch Surg 2006; 141:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/47\">",
"      Butturini G, Daskalaki D, Molinari E, et al. Pancreatic fistula: definition and current problems. J Hepatobiliary Pancreat Surg 2008; 15:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/48\">",
"      Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005; 138:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/49\">",
"      Connor S, Alexakis N, Garden OJ, et al. Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery. Br J Surg 2005; 92:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/50\">",
"      Yamamoto M, Hayashi MS, Nguyen NT, et al. Use of Seamguard to prevent pancreatic leak following distal pancreatectomy. Arch Surg 2009; 144:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/51\">",
"      Thaker RI, Matthews BD, Linehan DC, et al. Absorbable mesh reinforcement of a stapled pancreatic transection line reduces the leak rate with distal pancreatectomy. J Gastrointest Surg 2007; 11:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/32/2569/abstract/52\">",
"      Hawkins WG. To mesh or not to mesh, that is the question: comment on \"Use of Seamguard to prevent pancreatic leak following distal pancreatectomy\". Arch Surg 2009; 144:899.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5660 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-8D972B75FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_32_2569=[""].join("\n");
var outline_f2_32_2569=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Adenocarcinoma in body and tail of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neuroendocrine tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Premalignant and cystic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pseudocysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SURGEON'S SAFETY CHECKLIST FOR DISTAL PANCREATECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SURGICAL TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Open operation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Patient positioning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Initial exploration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Dissection and mobilization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Transection and closure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Drains",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Splenic preservation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Radical antegrade modular pancreaticosplenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Laparoscopic approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Patient positioning for laparoscopic approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Trocar placement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Laparoscopic approach for dissection and mobilization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Laparoscopic approach for transection and closure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Alternative approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      MORBIDITY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/5660\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/5660|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/33/7703\" title=\"figure 1\">",
"      Upper abdominal anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/22/32100\" title=\"figure 2\">",
"      Distal pancreatectomy with splenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/19/34101\" title=\"figure 3\">",
"      Spleen preserving distal pancreatectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/41/20115\" title=\"figure 4\">",
"      Port sites for laparoscopic pancreatectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/5660|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/45/15067\" title=\"table 1\">",
"      Sendai criteria for pancreatic resection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15686?source=related_link\">",
"      Classification of pancreatic cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=related_link\">",
"      Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28903?source=related_link\">",
"      Clinical features, diagnosis, and prevention of pancreatic fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35572?source=related_link\">",
"      Complications of chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17928?source=related_link\">",
"      Diagnosis and management of pseudocysts of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=related_link\">",
"      Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29591?source=related_link\">",
"      Endoscopic ultrasound in chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1929?source=related_link\">",
"      Endoscopic ultrasound in the staging of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=related_link\">",
"      Initial evaluation and management of blunt abdominal trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3368?source=related_link\">",
"      Pancreatic cystic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=related_link\">",
"      Pathology of exocrine pancreatic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/29/4567?source=related_link\">",
"      Physiology of somatostatin and its analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31369?source=related_link\">",
"      Treatment of chronic pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_32_2570="Birbeck granules";
var content_f2_32_2570=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F60620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F60620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Birbeck granules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 419px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This electron micrograph of a Langerhans' cell shows a number of typical Birbeck granules (arrow). (39,000 X).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Electron micrograph courtesy of Dr. Dominic V. Spagnolo, Perth, Western Australia. From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_32_2570=[""].join("\n");
var outline_f2_32_2570=null;
var title_f2_32_2571="Causes of light near dissociation";
var content_f2_32_2571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F60550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F60550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiologies of light-near dissociation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Bilateral anterior afferent visual pathway disease (retina, optic nerve, chiasm, tract)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dorsal midbrain lesions (eg, vascular, neoplastic, traumatic, demyelinating, toxic, ischemic, inflammatory)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Argyll Robertson pupil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes (autonomic neuropathy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tonic pupils (eg, local orbital disease, systemic neuropathic disorders, Adie's tonic pupil)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aberrant third nerve regeneration of the third nerve",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lee AG, Brazis PW. Clinical Pathways in Neuro-ophthalmology, Thieme, NY, 2002. Copyright &copy; 2002 Thieme Medical Publishers, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_32_2571=[""].join("\n");
var outline_f2_32_2571=null;
var title_f2_32_2572="Types of Mullerian anomalies";
var content_f2_32_2572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of M&uuml;llerian anomalies according to the American Fertility Society classification system",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Type I: \"M&uuml;llerian\" agenesis or hypoplasia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A. Vaginal (uterus may be normal or exhibit a variety of malformations)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       B. Cervical",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       C. Fundal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       D. Tubal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       E. Combined",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Type II: Unicornuate uterus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A1a. Communicating (endometrial cavity present)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A1b. Noncommunicating (endometrial cavity present)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A2. Horn without endometrial cavity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       B. No rudimentary horn",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Type III: Uterus didelphys",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Type IV: Uterus bicornuate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A. Complete (division down to internal os)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       B. Partial",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       C. Arcuate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Type V: Septate uterus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A. Complete (septum to internal os)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       B. Partial",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Type VI: Diethylstibestrol-related anomalies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A. T-shaped uterus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       B. T-shaped with dilated horns",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: American Fertility Society (AFS).",
"     <br>",
"      The American Fertility Society classifications of adnexal adhesions,distal tubal occlusion secondary to tubal ligation, tubal pregnancies, M&uuml;llerian anomalies and intrauterine adhesions. Fertil Steril 1988;49:944. Copyright &copy; 1988 American Society for Reproductive Medicine.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_32_2572=[""].join("\n");
var outline_f2_32_2572=null;
var title_f2_32_2573="NBG code pacing nomenclature";
var content_f2_32_2573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68327%7ECARD%2F79459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68327%7ECARD%2F79459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Revised NBG code for pacing nomenclature",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Position",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        V",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" rowspan=\"2\">",
"        Category",
"       </td>",
"       <td>",
"        Chamber(s) paced",
"       </td>",
"       <td>",
"        Chamber(s) sensed",
"       </td>",
"       <td>",
"        Response to sensing",
"       </td>",
"       <td>",
"        Rate modulation",
"       </td>",
"       <td>",
"        Multisite pacing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         0 = None",
"        </p>",
"        <p>",
"         A = Atrium",
"        </p>",
"        <p>",
"         V = Ventricle",
"        </p>",
"        <p>",
"         D = Dual (A+V)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0 = None",
"        </p>",
"        <p>",
"         A = Atrium",
"        </p>",
"        <p>",
"         V = Ventricle",
"        </p>",
"        <p>",
"         D = Dual (A+V)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0 = None",
"        </p>",
"        <p>",
"         T = Triggered",
"        </p>",
"        <p>",
"         I = Inhibited",
"        </p>",
"        <p>",
"         D = Dual (T+I)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0 = None",
"        </p>",
"        <p>",
"         R = Rate modulation",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0 = None",
"        </p>",
"        <p>",
"         A = Atrium",
"        </p>",
"        <p>",
"         V = Ventricle",
"        </p>",
"        <p>",
"         D = Dual (A+V)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Manufacturer's designation only:",
"       </td>",
"       <td>",
"        S = Single (A or V)",
"       </td>",
"       <td>",
"        S = Single (A or V)",
"       </td>",
"       <td colspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: Positions I through III are used exclusively for antibradyarrythmia function.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bernstein AD, Daubert JC, Fletcher RD, et al. Pacing Clin Electrophysiol 2002; 25:260.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of cardiac pacemakers and NBG codes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Code",
"       </td>",
"       <td class=\"subtitle1\">",
"        Meaning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VOO",
"       </td>",
"       <td>",
"        Asynchronous ventricular pacemaker; no adaptive rate control or antitachyarrhythmia functions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VVI",
"       </td>",
"       <td>",
"        Ventricular \"demand\" pacemaker with electrogram-waveform telemetry; no adaptive rate control or antitachyarrhythmia functions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DVI",
"       </td>",
"       <td>",
"        Multiprogrammable atrioventricular-sequential pacemaker; no adaptive rate control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DDD",
"       </td>",
"       <td>",
"        Multiprogrammable \"physiologic\" dual-chamber pacemaker; no adaptive rate control or antitachyarrhythmia functions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DDI",
"       </td>",
"       <td>",
"        Multiprogrammable",
"DDI pacemaker (with dual-chamber pacing and sensing but without",
"atrial-synchronous ventricular pacing); no adaptive rate control or",
"antitachycardia functions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VVIR",
"       </td>",
"       <td>",
"        Adaptive-rate VVI pacemaker with escape interval controlled adaptively by one or more unspecified variables",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DDDR",
"       </td>",
"       <td>",
"        Programmable DDD pacemaker with escape interval controlled adaptively by one or more unspecified variables",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_32_2573=[""].join("\n");
var outline_f2_32_2573=null;
var title_f2_32_2574="Mechanism of NH4 recycling";
var content_f2_32_2574=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Medullary recycling of ammonium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 282px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of ammonia recycling within the renal medulla. Although NH4+ production occurs primarily in the proximal tubule, most of the NH4+ is then reabsorbed in the thick ascending limb, apparently by substitution for K+ on the Na+-K+-2Cl- carrier in the luminal membrane. Partial dissociation into NH3 and H+ then occurs in the less acid tubular cell. The NH3 diffuses into the medullary interstitium where it achieves relatively high concentrations; it then diffuses back into those segments that have the lowest pH and therefore the favorable gradient: the S3 segment of the late proximal tubule and, more importantly, the medullary collecting tubule, where the secreted NH3 is trapped as NH4+ and then excreted.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_32_2574=[""].join("\n");
var outline_f2_32_2574=null;
var title_f2_32_2575="Asthma control 0 to 4 yrs";
var content_f2_32_2575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52149%7EPULM%2F73634%7EPULM%2F65972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52149%7EPULM%2F73634%7EPULM%2F65972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessing asthma control in children 0-4 years of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        Components of control",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Classification of asthma control (children 0-4 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Well-controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Not-well controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Very poorly controlled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Impairment",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        1x/month",
"       </td>",
"       <td>",
"        &gt;1x/month",
"       </td>",
"       <td>",
"        &gt;1x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Risk",
"       </td>",
"       <td>",
"        <strong>",
"         Exacerbations requiring oral systemic corticosteroids",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1/year",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2-3/year",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         &gt;3/year",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment-related adverse effects",
"       </td>",
"       <td colspan=\"3\">",
"        Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The level of control is based on the most severe impairment or risk category. Assess impairment domain by caregiver's recall of previous 2-4 weeks. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have not-well-controlled asthma, even in the absence of impairment levels consistent with persistent asthma.",
"    <div class=\"footnotes\">",
"     EIB: exercise-induced bronchospasm; ICU: intensive care unit.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessing asthma control in children 5-11 years of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        Components of control",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Classification of asthma control (children 5-11 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Well-controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Not-well controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Very poorly controlled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Impairment",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week but not more than once on each day",
"       </td>",
"       <td>",
"        &gt;2 days/week or multiple times on &le;2 days/week",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        &le;1x/month",
"       </td>",
"       <td>",
"        &ge;2x/month",
"       </td>",
"       <td>",
"        &ge;2x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        Lung function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        FEV",
"        <sub>",
"         1",
"        </sub>",
"        or peak flow",
"       </td>",
"       <td class=\"sublist_other\">",
"        &gt;80 percent predicted/personal best",
"       </td>",
"       <td class=\"sublist_other\">",
"        60-80 percent predicted/personal best",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;60 percent predicted/personal best",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        FEV",
"        <sub>",
"         1",
"        </sub>",
"        /FVC",
"       </td>",
"       <td class=\"sublist_other\">",
"        &gt;80 percent",
"       </td>",
"       <td class=\"sublist_other\">",
"        75-80 percent",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;75 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Risk",
"       </td>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Exacerbations requiring oral systemic corticosteroids",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1/year",
"        </strong>",
"       </td>",
"       <td colspan=\"2\">",
"        <strong>",
"         &ge;2/year (see footnote)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        <strong>",
"         Consider severity and interval since last exacerbation",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment-related adverse effects",
"       </td>",
"       <td colspan=\"3\">",
"        Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The level of control is based on the most severe impairment or risk category. Assess impairment domain by patient's/caregiver's recall of previous 2-4 weeks and by spirometry/or peak flow measures. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have not-well-controlled asthma, even in the absence of impairment levels consistent with not-well-controlled asthma.",
"    <div class=\"footnotes\">",
"     EIB: exercise-induced bronchospasm; FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in 1 second; FVC: forced vital capacity; ICU: intensive care unit.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessing asthma control in youths greater than or equal to 12 years of age and adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        Components of control",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Classification of asthma control (youths &ge;12 years of age and adults)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Well-controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Not-well controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Very poorly controlled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"9\">",
"        Impairment",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        &le;2x/month",
"       </td>",
"       <td>",
"        1-3x/week",
"       </td>",
"       <td>",
"        &ge;4x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FEV",
"        <sub>",
"         1",
"        </sub>",
"        or peak flow",
"       </td>",
"       <td>",
"        &gt;80 percent predicted/personal best",
"       </td>",
"       <td>",
"        60-80 percent predicted/personal best",
"       </td>",
"       <td>",
"        &lt;60 percent predicted/personal best",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        Validated questionnaires",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        ATAQ",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        1-2",
"       </td>",
"       <td class=\"sublist_other\">",
"        3-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        ACQ",
"       </td>",
"       <td class=\"sublist_other\">",
"        &le;0.75*",
"       </td>",
"       <td class=\"sublist_other\">",
"        &ge;1.5",
"       </td>",
"       <td class=\"sublist_other\">",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        ACT",
"       </td>",
"       <td class=\"sublist_other\">",
"        &ge;20",
"       </td>",
"       <td class=\"sublist_other\">",
"        16-19",
"       </td>",
"       <td class=\"sublist_other\">",
"        &le;15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Risk",
"       </td>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Exacerbations",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1/year",
"        </strong>",
"       </td>",
"       <td colspan=\"2\">",
"        <strong>",
"         &ge;2/year (see footnote)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        <strong>",
"         Consider severity and interval since last exacerbation",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progressive loss of lung function",
"       </td>",
"       <td colspan=\"3\">",
"        Evaluation requires long-term followup care",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment-related adverse effects",
"       </td>",
"       <td colspan=\"3\">",
"        Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The level of control is based on the most severe impairment or risk category. Assess impairment domain by patient's recall of previous 2-4 weeks and by spirometry/or peak flow measures. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have not-well-controlled asthma, even in the absence of impairment levels consistent with not-well-controlled asthma.",
"    <div class=\"footnotes\">",
"     EIB: exercise-induced bronchospasm; FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in 1 second; ATAQ: Asthma Therapy Assessment Questionnaire (Vollmer et al. 1999); ACQ: Asthma Control Questionnaire (Juniper et al. 1999b); ACT: Asthma Control Test (Nathan et al. 2004); N/A: not applicable.",
"     <br>",
"      * ACQ values of 0.76-1.4 are indeterminate regarding well-controlled asthma.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_32_2575=[""].join("\n");
var outline_f2_32_2575=null;
